预约演示
更新于：2026-06-01
Metformin Hydrochloride
盐酸二甲双胍
更新于：2026-06-01
概要
基本信息
简介盐酸二甲双胍，商品名为GLUCOPHAGE，用于治疗2型糖尿病。它于1957年在法国首次获批，现在由Bristol Myers Squibb公司生产。GLUCOPHAGE通过激活PRKAB1，帮助改善10岁及以上成人和儿童患者的血糖控制，配合饮食和运动使用。该药物属于双胍类药物，通常用作辅助疗法，帮助管理2型糖尿病患者的血糖水平。 |
药物类型 小分子化药 |
别名 Meiformin Hydrochloride、Metformin hydrochloride (JP17/USP)、Metformin Hydrochlorride + [67] |
靶点 |
作用方式 激活剂 |
作用机制 PRKAB1激活剂(腺苷酸活化蛋白激酶亚基β1激活剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 中国 (1992-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C4H12ClN5 |
InChIKeyOETHQSJEHLVLGH-UHFFFAOYSA-N |
CAS号1115-70-4 |
关联
2,842
项与 盐酸二甲双胍 相关的临床试验CTRI/2025/09/094234
A Feasibility Study Comparing a Unani Regimen and Metformin in the management of Type 2 Diabetes Mellitus - NIL
开始日期2027-10-01 |
申办/合作机构- |
NCT07511010
A Phase I Clinical Study to Assess the Food Effect and Multiple Dose Pharmacokinetic of Chiglitazar/Metformin Extended-Release Fixed Dose Combination Tablets
This trial includes two parts: a food effect (FE) study and a multiple-dose pharmacokinetic (PK) study.
The FE study is a randomized, open-label, two-period, two-sequence crossover study designed to evaluate the effect of a high-fat meal on the PK of a single oral dose of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants.
The multiple-dose PK study is an open-label study designed to evaluate the PK characteristics of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants following multiple oral doses.
The FE study is a randomized, open-label, two-period, two-sequence crossover study designed to evaluate the effect of a high-fat meal on the PK of a single oral dose of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants.
The multiple-dose PK study is an open-label study designed to evaluate the PK characteristics of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants following multiple oral doses.
开始日期2026-10-08 |
申办/合作机构 |
NCT07275359
Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations
The purpose of this study is to investigate the safety and tolerability of Metformin and how it changes blood markers associated with aging in persons who have chronic obstructive pulmonary disease (COPD) who do not have diabetes.
开始日期2026-09-01 |
申办/合作机构  Duke University [+1] |
100 项与 盐酸二甲双胍 相关的临床结果
登录后查看更多信息
100 项与 盐酸二甲双胍 相关的转化医学
登录后查看更多信息
100 项与 盐酸二甲双胍 相关的专利（医药）
登录后查看更多信息
12,514
项与 盐酸二甲双胍 相关的文献（医药）2026-05-04·Expert Opinion On Drug Safety
Potential drugs for reducing the occurrence of immune checkpoint inhibitor-induced interstitial lung disease: an exploratory study using the JADER and FAERS databases
Article
作者: Koseki, Takenao ; Kondo, Masashi ; Hatano, Masakazu ; Utsunomiya, Ayaka ; Yamada, Shigeki ; Imaizumi, Kazuyoshi
BACKGROUND:
Immune checkpoint inhibitors (ICIs) play a central role in cancer immunotherapy. However, the occurrence of immune-related adverse events, especially ICI-induced interstitial lung disease (ICI-ILD), is life-threatening and affects the effectiveness of ICI treatment. This study aimed to explore potential drugs to mitigate ICI-ILD occurrence using data from the Japanese Adverse Drug Event Report (JADER) and the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS [JAPIC AERS]).
RESEARCH DESIGN AND METHODS:
We investigated concomitant drugs that reduce ILD associated with four ICIs - nivolumab, pembrolizumab, atezolizumab, and durvalumab - across the JADER and FAERS databases. Subsequently, the identified common concomitant drugs that reduce the occurrence of ICI-ILD were detected and analyzed.
RESULTS:
We found omega-3 fatty acids, loperamide, and amlodipine as common concomitant drugs that reduced ICI-ILD occurrence in both the JADER and FAERS databases. Omega-3 fatty acids reportedly have many effects in animal models of drug-induced ILD, including their association with ILD in humans and anti-inflammatory effects against ICI-ILD. However, loperamide and amlodipine reportedly have minimal effects against ILD, thereby necessitating further evaluation.
CONCLUSION:
Omega-3 fatty acids have emerged as potential agents for reducing ICI-ILD occurrence, as evidenced by findings from two different pharmacovigilance databases.
2026-05-01·Clinical Pharmacology in Drug Development
Comparative Pharmacokinetics and Bioequivalence Assessment of Metformin/Pioglitazone Tablet in Fasting and Fed Conditions: A Randomized Study in Healthy Chinese Subjects.
Article
作者: Wei, Zijie ; Wang, Xintong ; Li, Mengke ; Chen, Lulu ; Ouyang, Dongsheng ; Liu, Bin ; Li, Chao ; Zhou, Ling ; Li, Xiaohui ; Li, Hongcheng ; Fang, Qing
Metformin/pioglitazone tablets are a fixed-dose combination of metformin hydrochloride and pioglitazone. In healthy Chinese subjects, this study evaluated the pharmacokinetics and bioequivalence of metformin/pioglitazone (500/15 mg) tablets. We conducted a single-center, open-label, randomized, two-way crossover study in which subjects were randomized in a 1:1 ratio to either the test formulation or the reference formulation, separated by a 10-day washout period. Blood samples collected at pre-arranged intervals before and after dosing were analyzed using validated liquid chromatography-tandem mass spectrometry techniques to determine metformin and pioglitazone plasma concentrations. Finally, subjects completed fasting and fed studies, respectively. In both studies, the 90% confidence intervals for the geometric mean ratios (test/reference) of Cmax, AUC0-t, and AUC0-∞ were within acceptable bioequivalence limits (0.80-1.25), and no serious adverse events were observed. The study demonstrated that the tested and reference formulations of metformin/pioglitazone tablets are bioequivalent and well tolerated under both fasting and fed conditions.
2026-04-21·JOURNAL OF VIROLOGY
Metformin hydrochloride regulates glycolysis and inhibits PEDV replication by inhibition of PI3K-AKT signaling pathway
Article
作者: Song, Ziyan ; Song, Yanwen ; Ding, Jinman ; Yang, Shu ; Sun, Zhiwei ; Zhang, Xingcui ; Song, Zhenhui ; Li, Yi ; Liao, Guisong ; Hu, Xiaoru ; Zhong, Yi ; Li, Qingyang ; Yuan, Jianbo
ABSTRACT:
Viruses rely on energy and biosynthetic materials of host cell from glucose metabolism to support their replication, and glucose plays a crucial role in viral infection. In this study, we found that porcine epidemic diarrhea virus (PEDV) infection significantly increased cellular glucose uptake and stimulated the production of the glycometabolite lactate. Exogenous supplementation of glucose or L-lactate confirmed that it significantly promoted PEDV proliferation, indicating that replication of PEDV was enhanced by regulating host glucose metabolism, particularly reprogramming glycolysis. Based on these findings, we explored the potential antiviral approach targeting the virus through regulating glycolytic processes. Metformin hydrochloride (MH) is a well-known hypoglycemic agent, which has shown notable anti-PEDV activity. After MH treatment, the transcriptome analysis showed the differential genes were mainly enriched in PI3K-AKT signaling pathway, and the expression levels of its downstream molecule GSK3B and MYC were significantly upregulated and downregulated, respectively. The gene expression related to glycolysis was also significantly inhibited. Further experiments showed that MH significantly inhibited the phosphorylation of AKT and its translocation to plasma membrane, while reducing the phosphorylation level of GSK3B. MH maintained GSK3B in a non-phosphorylated state by blocking the activation of the EGFR/PI3K/AKT/GSK3B pathway, mediated the degradation of c-MYC through phosphorylation, inhibited the glycolysis process, reduced the production of lactic acid, and finally exerted its antiviral effect. This study demonstrated that PEDV infection could induce glycolysis through metabolic reprogramming, thereby promoting viral replication; whereas, MH was able to effectively reverse this process, significantly inhibiting the virus-induced glycolysis pathway and exhibiting antiviral activity.
IMPORTANCE:
This study aims to elucidate the antiviral effects and molecular mechanisms of MH against PEDV. The results show that MH can inhibit the activation of the PI3K-AKT signaling pathway induced by PEDV infection, thereby suppressing the production of the glycolytic product L-lactic acid and ultimately resisting PEDV infection. This research provides new insights into the prevention and control of PEDV and offers scientific evidence for the application of MH in veterinary medicine.
1,521
项与 盐酸二甲双胍 相关的新闻（医药）2026-06-01
·药通社
药通社盘点：每月首仿获批情况。
2026年5月，共计467条受理号过评/视同过评，涉及个225品种，其中首家过评品种14个，其中10款为首仿。
本月的首仿角逐，仿制药大厂呈现出一种竞争同频的情况，西尼莫德片， 齐鲁和科伦同日过评，阿贝西利片，青峰医药首仿后不到二十天，齐鲁就过评了。
从这些首仿品种也可看出，国内的仿制药不再聚焦于大普药，而是开始转向特需药物，肿瘤、罕见病、神经系统领域等等。
1
利多卡因丁卡因乳膏
5.6
利多卡因丁卡因乳膏是一种用于皮肤表皮手术的局部复合表皮麻醉乳膏剂，利多卡因和丁卡因组合配方可产生快速且持久的麻醉效果，是科笛首个自研获批的品种，
利多卡因丁卡因乳膏是个真3类，科笛首仿获批日期在数据保护落地前，以目前的政策看，不受数据保护。
科笛为了上市这一品种，付出了相当多的时间与精力，在2023年完成了有效性和安全性的3期临床研究，共招募了286例受试者，2024年7月，科笛首家提交上市申请，经过近两年审批才终于获批。
除了科笛之外，此品种还有3家也提交了上市申请，北京诺博特生物科技有限公司、浙江孚诺医药股份有限公司，以及江苏盈科生物制药有限公司，这三家都完成了3期才提报上市。
在科笛斩获首仿之后，依据数据保护政策，后面申请上市将免除安全性和有效性临床试验，对几家企业而言可不是好消息。
2
马立巴韦片
5.21
马立巴韦片是一种抗病毒药物，作为全球首个且目前唯一一个靶向并抑制UL97蛋白激酶及其天然底物的抗病毒制剂，全新机制能用于耐药型病毒，马立巴韦片原研为武田制药，2021年11月首次获美国FDA批准上市，2023年12月19日在中国获批上市。
5月21日，桂林南药顺利斩获首仿，这一品种无专利限制，获批就能销售。
马立巴韦片填补了移植后难治/耐药CMV治疗的临床空白，2025年起纳入国家医保谈判目录，25年就完成了五千多万，增长率惊人。
这款药售价惊人，经医保谈判后依旧高达436元/片，仿制药上市将给患者提供新的选择。
马立巴韦片仿制有齐鲁的身影，目前申报上市的企业江苏奥赛康、齐鲁、人福，奥赛康申报上市时间早于齐鲁，但目前审评是暂停状态，反观齐鲁补充资料已经进入了审评状态，第二家不出意外是齐鲁。
3
西尼莫德片
5.21
西尼莫德片适用于成人复发型多发性硬化症的治疗，多发性硬化症（MS）是一种罕见病目前全球约有多发性硬化症患者300万人，该疾病迄今仍无法治愈。
该品种由诺华公司研发，2020年5月获中国批准进口上市，获批当年即谈判成功进入国家医保目录，2024年转入国家医保常规目录。
该品种国内市场规模不大，25年全终端医院仅三千万元，此前皆为诺华独家。
湖南科伦制药于2023年2月首家提交该品种4类仿制上市申请，齐鲁制药紧随其后，于2024年1月4日获受理，历经两年多，科伦和齐鲁于2026年5月21日同日成功获批，两家药企同日斩获国内首家+首仿。
4
甲磺酸沙非胺片
5.21
甲磺酸沙非胺片由意大利赞邦集团与Newron制药公司合作研发，用于治疗接受稳定剂量左旋多巴治疗后出现运动波动的特发性帕金森病。
该药2024年12月在中国获批后，科伦、齐鲁制药、华海药业、扬子江等超20家企业纷纷入局首仿竞逐，最终科伦斩获首仿。
这款药也是仿制药围剿原研的典型，原研赞邦在24年12月1日获批，20日，CDE就受理了科伦和石四药的仿制上市申请，在原研上市前，南京正大天晴按照3类申报上市，未通过，在原研上市后立刻重新以4类提交了上市（24年12月21日），这一品种，同样有齐鲁的身影。
甲磺酸沙非胺片，优点在于赞邦在国内没有专利限制权，仿制药获批就能卖，缺点在产品没进医保，目前销售情况很差，仿制药企业要自行布局商业化。
5
酒石酸阿福特罗吸入溶液
5.29
酒石酸阿福特罗吸入溶液的原研厂家为Sunovion制药，2006年10月获FDA批准，适用于慢性阻塞性肺疾病（COPD）患者支气管收缩的长期维持治疗，包括慢性支气管炎和肺气肿。
酒石酸阿福特罗的产品优势在于治疗中重度COPD安全有效，耐受性好，并且对肺功能也有改善作用，这款吸入溶液原研一直未在国内上市，故而被列入了第二批鼓励仿制目录。
江苏长泰在2021年直接报产未被批准，后重新申报临床，并完成了240例临床后重新申报，最终顺利获批，从江苏长泰立项此品种到获批已经超过了10年，可谓困难重重。
此品种目前还有正大天晴和华纳大药厂两家企业在走审评流程，这一品种也是个真3类品种，不出意外的话将受到数据保护，后两家企业的审评不知会如何。
6
其他
3款
另外还有华阳的诊断用药荧光素钠注射液，信立泰的降脂新剂型匹伐他汀钙口崩片，安徽新世纪的盐酸二甲双胍口服溶液，青峰医药的阿贝西利片和布立西坦注射液，顺利获批，详见分析青峰医药，又一款独家！礼来大药，首仿刚批，第三家申报上市！
5月的首仿，科伦获得两款，青峰医药获得两款，齐鲁虽然只有一款，但这些品种首仿后的第二家第三家都有齐鲁的身影，齐鲁在固体制剂和注射剂的统治力惊人，医药界隐形航母真不是浪得虚名。
↓⭐关注药通社，洞见行业趋势↓
2026-05-31
Clinical Infectious Diseases Volume 82 Issue 1
临床传染病学 82卷1期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病学技艺）
1
Peasants' Revolt, 1381
1381年农民起义
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page i, https://doi.org/10.1093/cid/ciaf692
In the Literature（文献概览）
2
In the Literature
文献概览
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages ii–iii, https://doi.org/10.1093/cid/ciaf631
State-of-the-Art Review（最新技术综述）
3
State-of-the-Art Review: Diagnosis and Management of Acute and Chronic Bacterial Prostatitis
最新技术综述：急性和慢性细菌性前列腺炎的诊断与治疗
Prathit A Kulkarni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 1–13, https://doi.org/10.1093/cid/ciaf483
Clinical Dilemmas in Infectious Diseases（传染病临床难题）
4
“Insisting on Treatment”
“坚持治疗”
Kevin Andrew Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 14–18, https://doi.org/10.1093/cid/ciaf282
Voices of ID（传染病之声）
5
Martin Arrowsmith and Me
马丁·阿罗史密斯与我
Janet R Gilsdorf
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 19–20, https://doi.org/10.1093/cid/ciaf277
Invited Commentary（特邀述评）
6
The 2025 Centers for Disease Control and Prevention Nonoccupational HIV Postexposure Prophylaxis Guidelines: Updated Regimens and Remaining Questions
2025年美国疾病控制与预防中心非职业性艾滋病毒暴露后预防指南：更新方案及遗留问题
Lao-Tzu Allan-Blitz and Kenneth H Mayer
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 21–24, https://doi.org/10.1093/cid/ciaf567
Antimicrobial Resistance and Stewardship（抗菌药物耐药性与管控）
7
Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings
资源有限环境下，基于培养的分子检测法对抗菌药物耐药性的影响和成本建模
Joshua M Chevalier and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 25–32, https://doi.org/10.1093/cid/ciaf236
8
The Xpert MTB/RIF Cycle Threshold Value Predicts Mycobacterium tuberculosis Transmission to Close Contacts in a Brazilian Prospective Multicenter Cohort
巴西一项前瞻性多中心队列研究中Xpert MTB/RIF循环阈值可预测结核分枝杆菌在密切接触者中的传播
Leandro S Garcia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 33–41, https://doi.org/10.1093/cid/ciad794
9
Beyond Diagnosis: Xpert Cycle Threshold Values as Predictors of Tuberculosis Transmission
超越诊断：Xpert循环阈值作为结核病传播的预测指标
Lauren Linde and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 42–43, https://doi.org/10.1093/cid/ciad791
10
First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa
铜绿假单胞菌在头孢吡肟-齐德巴坦治疗中出现耐药性的首例报告
Ava J Dorazio and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 44–48, https://doi.org/10.1093/cid/ciaf638
Clinical Practice and Policy（临床实践与政策）
11
Sputum and Tongue Swab Molecular Testing for the In-Home Diagnosis of Tuberculosis in Unselected Household Contacts: A Cost and Cost-Effectiveness Analysis
痰液和舌拭子分子检测用于未筛选家庭接触者结核病居家诊断的成本及成本效益分析
Charl Bezuidenhout and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 49–57, https://doi.org/10.1093/cid/ciaf389
12
You’ve Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists
我是你的朋友：传染病临床医生向传染病药剂师咨询的即兴问题
Matthew R Davis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 58–61, https://doi.org/10.1093/cid/ciaf250
13
Home Testing for Contagious Illness: Historical Context and Modern Caveats
传染性疾病居家检测：历史背景与现代注意事项
Abigail Zuger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 62–66, https://doi.org/10.1093/cid/ciaf623
Fungal Infections（真菌感染）
14
Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial
评估低剂量氟胞嘧啶治疗隐球菌性脑膜炎的临床试验
Morris K Rutakingirwa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 67–74, https://doi.org/10.1093/cid/ciaf432
15
Association Between Duration of Candidemia and Clinical and Healthcare Resource Utilization Outcomes Among Hospitalized Adult Patients With Candidemia Who Received Empiric Treatment With an Echinocandin Across United States Hospitals
美国各医院中接受棘白菌素经验性治疗的念珠菌血症成年住院患者中，念珠菌血症持续时间与临床和医疗资源利用结局之间的关联
Thomas P Lodise and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 75–85, https://doi.org/10.1093/cid/ciaf472
16
Aspergillosis-Attributable Mortality in the United States: Analysis of Death Certificate Data
美国隐球菌病导致的死亡率分析：基于死亡证明数据
Thomas J Walsh and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 86–92, https://doi.org/10.1093/cid/ciaf653
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
17
Outcomes of Critical Illness in People With Advanced HIV Disease: 30 Years of Binational Data
晚期艾滋病患者危重症结局：30年的双国数据
Bryan Tan and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 93–99, https://doi.org/10.1093/cid/ciaf362
18
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357
长效卡博特韦和VRC07-523LS用于HIV-1感染成人病毒抑制的2期试验：ACTG A5357
Babafemi O Taiwo and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 100–108, https://doi.org/10.1093/cid/ciaf375
19
Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study
全国HIV-1感染者队列中长效卡博特韦和利匹韦林的治疗药物监测：ANRS-MIE CARLAPOP研究的首批结果
Nadège Néant and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 109–118, https://doi.org/10.1093/cid/ciaf385
20
Is Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine of Clinical Utility?
长效卡博特韦和利匹韦林的治疗药物监测是否具有临床实用性？
Catia Marzolini
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 119–121, https://doi.org/10.1093/cid/ciaf386
21
Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study
多替拉韦/拉米夫定双药治疗在CD4计数<200/mm³的初治患者中的疗效和安全性：DOLCE研究48周结果
Maria Ines Figueroa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 122–131, https://doi.org/10.1093/cid/ciaf415
22
DOLCE: Sweet Success for Dolutegravir/Lamivudine?
DOLCE研究：多替拉韦/拉米夫定双药治疗是否取得完美成功？
Laura J Waters
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 132–133, https://doi.org/10.1093/cid/ciaf416
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
23
Real-Time Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control: Clinical and Economic Impact
实时基因组监测用于加强医疗保健机构疫情检测与控制：临床与经济影响
Alexander J Sundermann and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 134–141, https://doi.org/10.1093/cid/ciaf216
24
Patient Perspectives Regarding Different Contact Precaution Policies for Methicillin-resistant Staphylococcus aureus Across Two Hospitals: Patients Are in Favor of Contact Precautions
两家医院患者对耐甲氧西林金黄色葡萄球菌不同接触预防政策的态度：患者支持接触预防措施
Nicholas F Angelino and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 142–144, https://doi.org/10.1093/cid/ciaf330
Photo Quiz（影像问答）
25
The Clue That Wriggled into View
蜿蜒入目的线索
Nitin Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 145–147, https://doi.org/10.1093/cid/ciaf427
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
26
Comparing Generative Artificial Intelligence vs Experts for Detection of Catheter-Associated Urinary Tract Infection
比较生成式人工智能与专家在导管相关尿路感染检测中的应用
Shatha Alshanqeeti and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 148–150, https://doi.org/10.1093/cid/ciaf486
Sexually Transmitted Infections（性传播感染）
27
Viability of Chlamydia trachomatis in Different Anatomical Sites—a Systematic Review and Meta-analysis
不同解剖部位沙眼衣原体的存活能力——系统综述和荟萃分析
Arthur Wong and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 151–158, https://doi.org/10.1093/cid/ciae401
Photo Quiz（影像问答）
28
A 46-Year-Old With Persistent Altered Mental Status and Respiratory Failure
一例46岁患者持续出现意识状态改变伴呼吸衰竭
Ann F Yang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 159–161, https://doi.org/10.1093/cid/ciaf439
Sexually Transmitted Infections（性传播感染）
29
Mpox in People With HIV: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort
HIV感染者中的猴痘：多站点队列中诊断、预后和疫苗有效性的预测因素
Michalina Montaño and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 162–172, https://doi.org/10.1093/cid/ciae464
30
Development and Evaluation of a Novel Algorithm to Identify Doxycycline Postexposure Prophylaxis Users at a Large Healthcare System in the Bronx, New York
开发和评估一种新型算法，用于识别纽约布朗克斯区一家大型医疗系统中多西环素暴露后预防用药者
Caroline E Mullis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 173–176, https://doi.org/10.1093/cid/ciaf109
31
Evidence-Informed Provision of Doxycycline Postexposure Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections
为预防细菌性性传播感染提供基于证据的多西环素暴露后预防用药
Julia C Dombrowski and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 177–184, https://doi.org/10.1093/cid/ciae527
Bacterial Infections（细菌性感染）
32
Long-term Mortality Trends Among Individuals With Tuberculosis: A Retrospective Cohort Study of Individuals Diagnosed With Tuberculosis in Brazil
巴西结核病患者的长期死亡率趋势：一项针对巴西结核病诊断患者的回顾性队列研究
Sun Kim and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e1–e8, https://doi.org/10.1093/cid/ciaf206
33
Clinical and Microbiological Characteristics of Meningococcal Eye Infections: Retrospective National Surveillance in England, 2010–2022
脑膜炎球菌眼部感染的临床和微生物学特征：2010 - 2022年英格兰全国回顾性监测
Stephen A Clark and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e9–e16, https://doi.org/10.1093/cid/ciaf274
34
Does Piperacillin-Tazobactam Increase Mortality Risk Compared With Cefepime? Collider Bias and the Importance of Assumptions in Instrumental Variable Analyses
与头孢吡肟相比，哌拉西林-他唑巴坦是否会增加死亡率风险？工具变量分析中的混杂偏倚和假设的重要性
Fergus Hamilton and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e17–e23, https://doi.org/10.1093/cid/ciaf317
COVID-19 / SARS COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
35
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
奥贝德西韦在高危非住院COVID-19患者（BIRCH研究）中的疗效和安全性：一项3期、随机、双盲、安慰剂对照研究
Anca Streinu-Cercel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e24–e32, https://doi.org/10.1093/cid/ciaf406
36
Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity
COVID-19症状复发且SARS-CoV-2检测呈阳性后使用奈玛特韦/利托那韦重新治疗
Wuyan Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e33–e40, https://doi.org/10.1093/cid/ciaf548
Emerging Infections(新兴感染)
37
“I Didn’t Know Him Before the Pandemic… Now He's on My Speed Dial”: Strengthening Collaboration Between Infectious Diseases Physicians and State and Local Public Health for Future Public Health Emergencies
“疫情前我并不认识他……现在他已是我的快速拨号对象”：加强传染病医生与州和地方公共卫生部门在未来突发公共卫生事件中的合作
Diana Valencia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e41–e46, https://doi.org/10.1093/cid/ciaf179
38
Identification of and Response to Influenza A(H5) in Off-the-Shelf Raw Milk—Santa Clara County, California, November–December 2024
2024年11 - 12月加利福尼亚州圣克拉拉县在现成生牛奶中检出甲型流感（H5）病毒及应对措施
Alessandra Løchen and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e47–e48, https://doi.org/10.1093/cid/ciaf420
39
The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness
小分子抗病毒药物在流行病和大流行病防范中的不可或缺价值
Ruxandra Draghia-Akli and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e49–e55, https://doi.org/10.1093/cid/ciaf476
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
40
Increasing HIV Testing During Gonorrhea and Chlamydia Evaluations in Urgent Care and Emergency Departments: A Large Health System Initiative
在紧急护理和急诊科进行淋病和衣原体检测时增加HIV检测：一项大型医疗系统倡议
Allan M Seibert and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e56–e67, https://doi.org/10.1093/cid/ciaf434
41
Clinical Predictors and Incidence of Kaposi Sarcoma Among Males With HIV in the Treat-All Era in the United States and Canada
美国和加拿大“全员治疗”时代男性HIV感染者卡波西肉瘤的临床预测因素和发病率
Sally B Coburn and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e68–e77, https://doi.org/10.1093/cid/ciaf446
42
Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes
美国接受过治疗的围产期感染HIV的年轻成人使用整合酶链转移抑制剂的免疫学、病毒学和人体测量学结果
Kunjal Patel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e78–e88, https://doi.org/10.1093/cid/ciaf538
43
Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings
Win比值与REPRIEVE研究的主要发现一致并增强了其解释性
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e89–e92, https://doi.org/10.1093/cid/ciaf477
44
The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States
临床应用案例对于指导即时检测技术开发的重要性：以美国HIV核酸检测为例
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e93–e99, https://doi.org/10.1093/cid/ciaf510
Mycobacterial Infections（分枝杆菌感染）
45
Body Mass Index and Incident Tuberculosis in Close Tuberculosis Contacts
结核密切接触者中体重指数与新发结核病的关系
María B Arriaga and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e100–e109, https://doi.org/10.1093/cid/ciaf475
46
The Role of Youths in Within-Household Tuberculosis Transmission: A Household Contact Cohort Study
青年在家庭内结核病传播中的作用：一项家庭接触队列研究
Meredith B Brooks and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e110–e118, https://doi.org/10.1093/cid/ciaf490
47
Cost-effectiveness of Targeted Next-Generation Sequencing for Tuberculosis Drug-resistance Testing as an Alternative to the Standard of Care in South Africa
南非以靶向下一代测序作为结核病耐药检测标准护理方案的替代方案的成本效益分析
Alexandra de Nooy and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e119–e125, https://doi.org/10.1093/cid/ciaf495
48
Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification
Xpert MTB/RIF循环阈值作为结核病（TB）疾病严重程度的标志物：对结核病治疗分层的启示
Daniel J Grint and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e126–e134, https://doi.org/10.1093/cid/ciaf527
49
The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials
β-内酰胺类抗生素在治疗脓肿分枝杆菌中的作用：从实验室见解到临床应用及开展临床试验的必要性
Khalid M Dousa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e135–e145, https://doi.org/10.1093/cid/ciaf547
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
50
Efficacy, Immunogenicity, and Safety of an Investigational Maternal Respiratory Syncytial Virus Prefusion F Protein–Based Vaccine
一种研究性孕产妇呼吸道合胞病毒融合前F蛋白疫苗的疗效、免疫原性和安全性
Peyman Banooni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e146–e155, https://doi.org/10.1093/cid/ciaf033
51
Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics
HIV感染者在孕期和产后接受异烟肼预防性治疗时的肝毒性：抗逆转录病毒治疗方案和药物基因组学的作用
Grace Montepiedra and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e156–e164, https://doi.org/10.1093/cid/ciaf198
52
Transplacental Transfer of Lumefantrine, Mefloquine, and Piperaquine: A Comparison of Concentrations in Mothers, Neonates, and Cord Blood
青蒿素、甲氟喹和哌喹的胎盘转运：母亲、新生儿和脐带血中浓度的比较
Makoto Saito and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e165–e173, https://doi.org/10.1093/cid/ciaf552
53
Why Did the Antimalarial Drug Cross the Placenta?
抗疟药为何要穿过胎盘？
Stephen J Rogerson and Holger W Unger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e174–e175, https://doi.org/10.1093/cid/ciaf553
Viral Infections（病毒性传染病）
54
Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection
HIV和慢性乙型肝炎病毒（HBV）共感染患者开始使用HBV活性抗逆转录病毒治疗后乙型肝炎表面抗原消失的动力学和预测因素
Jennifer Audsley and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e176–e184, https://doi.org/10.1093/cid/ciaf281
55
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病
Lauren A Powers and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e185–e190, https://doi.org/10.1093/cid/ciaf285
Correspondence（读者来信）
56
Unveiling Latent Risk Patterns in Antimicrobial-Resistant Bacteremia: A Deeper Look at Pathogen-Specific Mortality
揭示抗菌药物耐药性菌血症中的潜在风险模式：深入探究病原体特异性死亡率
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e191, https://doi.org/10.1093/cid/ciaf493
57
Resistance to Antibiotics With High Empiric Treatment Relevance Explains Attributable Mortality Across 110 Pathogen-antibiotic Combinations
对经验性治疗具有高度相关性的抗生素耐药性可解释110种病原体 - 抗生素组合的归因死亡率
Kevin A Brown and Nick Daneman
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e191–e192, https://doi.org/10.1093/cid/ciaf494
58
Culture Clash: Dual-Pathogen Endocarditis and the Metagenomic Next-Generation Sequencing Studies We Need
文化冲突：双病原体心内膜炎以及我们所需的宏基因组下一代测序研究
Carl Boodman and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e193–e195, https://doi.org/10.1093/cid/ciaf518
59
Metagenomic Next-Generation Sequencing and Cardiovascular Infections: Promise and Pitfalls of Polymicrobial Detection
宏基因组下一代测序与心血管感染：多微生物检测的前景与陷阱
Sarwat Khalil and M Rizwan Sohail
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e196, https://doi.org/10.1093/cid/ciaf519
60
It Is Time to Go Beyond the Association Between Colistin and Meropenem for Invasive Carbapenem-Resistant Acinetobacter baumannii Infections
是时候超越多粘菌素和美罗培南联合治疗侵袭性碳青霉烯耐药鲍曼不动杆菌感染了
Alberto Enrico Maraolo and Giancarlo Ceccarelli
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e197–e198, https://doi.org/10.1093/cid/ciaf533
61
Actually, It May be Time to Return to Colistin and Meropenem in Some Patients Infected With Carbapenem-resistant Acinetobacter baumannii (CRAB)
实际上，对于某些感染碳青霉烯耐药鲍曼不动杆菌（CRAB）的患者，或许是时候重新使用多粘菌素和美罗培南了
Jason M Pogue and Keith S Kaye
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e198–e199, https://doi.org/10.1093/cid/ciaf534
62
COVID-19 and Bacterial Pneumonia: Protective Effect or Diagnostic Bias?
COVID-19和细菌性肺炎：保护作用还是诊断偏差？
Duygu Aydın and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e200, https://doi.org/10.1093/cid/ciaf539
63
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections: A Follow Up
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病：后续研究
John C Hu and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e200–e201, https://doi.org/10.1093/cid/ciaf540
64
Long-Acting Cabotegravir/Rilpivirine in Viremic People With HIV: Bumpy Road to Perfection
长效卡博特韦/利匹韦林用于病毒载量阳性的HIV感染者：通往完美的坎坷之路
Beatrice Barda and Marco Bongiovanni
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e201–e202, https://doi.org/10.1093/cid/ciaf482
65
Beyond the Sequence: Operationalizing Whole-Genome Sequencing for Real-time Infection Control in Low- and Middle-Income-Country Healthcare Settings Healthcare Settings
超越序列：在中低收入国家医疗环境中实际应用全基因组测序进行实时感染控制
Schawanya Kaewpitoon Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e202–e203, https://doi.org/10.1093/cid/ciaf535
66
Reassessing Adherence Trajectories in Multidrug-Resistant Tuberculosis: Recovery Advantage and Hidden Biases
重新评估耐多药结核病的依从性轨迹：康复优势和隐藏偏差
Shiuan-Chih Chen and Chun-Chieh Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e203–e204, https://doi.org/10.1093/cid/ciaf536
67
Metagenomic Sequencing of Blood Culture Broth for Diagnosing Fastidious Endocarditis
血培养肉汤宏基因组测序用于诊断苛养性心内膜炎
Po-Hsiu Huang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e204–e205, https://doi.org/10.1093/cid/ciaf554
Corrections（更正）
68
Correction to: Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
《患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e206, https://doi.org/10.1093/cid/ciaf572
69
Correction to: Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa
《南非高HIV流行率、项目化环境中口服短程利福平耐药结核病治疗方案的治疗结果》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e207, https://doi.org/10.1093/cid/ciaf711
Clinical Infectious Diseases Volume 82 Issue Supplement_1
临床传染病学 82卷 增刊1期
https://academic.oup.com/cid/issue/82/Supplement_1
SUPPLEMENT（增刊）
Laboratory and Point-of-care Testing to Detect Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Available Evidence
实验室及即时检测技术用于检测沙眼衣原体和淋病奈瑟菌：现有证据综述
SUPPLEMENT ARTICLES（增刊论著）
1
Evidence Review for Centers for Disease Control and Prevention Guidance Development on the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae
美国疾病控制与预防中心沙眼衣原体和淋病奈瑟菌检测指南制定证据综述
Amanda C Smith and Ellen N Kersh
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S1–S5, https://doi.org/10.1093/cid/ciaf665
2
Narrative Review of Chlamydia trachomatis Culture, Viability Testing, and Sequencing Methods
沙眼衣原体培养、活性检测及测序方法的叙述性综述
Alana K Sterkel and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S6–S12, https://doi.org/10.1093/cid/ciaf697
3
Culture and Identification of Neisseria gonorrhoeae: A Narrative Review of Current Laboratory Methods
淋病奈瑟菌培养与鉴定：当前实验室方法叙述性综述
Olusegun O Soge and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S13–S18, https://doi.org/10.1093/cid/ciaf698
4
Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae
实验室分子诊断技术检测沙眼衣原体和淋病奈瑟菌的性能综述
Megan Crumpler and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S19–S35, https://doi.org/10.1093/cid/ciaf696
5
Review of Methods for Detecting Antimicrobial Resistance of Neisseria gonorrhoeae
淋病奈瑟菌抗菌药物耐药性检测方法综述
Kara K Mitchell and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S36–S42, https://doi.org/10.1093/cid/ciaf706
6
Point-of-care Tests for Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Literature
沙眼衣原体和淋病奈瑟菌即时检测技术文献综述
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S43–S51, https://doi.org/10.1093/cid/ciaf699
Clinical Infectious Diseases Volume 82 Issue 2
临床传染病学 82卷 2期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Interior of the Old Jersey Prison Ship in the Revolutionary War
美国革命战争中老泽西监狱船的内部景象
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page i, https://doi.org/10.1093/cid/ciaf693
In the Literature（本期精选）
2
In the Literature
本期精选
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag011
IDSA 2025 Collections Editorial（美国传染病学会2025年专题合集社论）
3
2025 Content Collections from the IDSA Journals
IDSA期刊2025年内容合集
Roger Bedimo and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 185–186, https://doi.org/10.1093/cid/ciag041
State-of-the-Art Review（前沿综述）
4
State-of-the-Art Review: Chagas Disease—an Enduring Challenge
前沿综述：恰加斯病——一个持续存在的挑战
Nelson Iván Agudelo Higuita and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 187–205, https://doi.org/10.1093/cid/ciaf654
IDSA Features（美国传染病学会特色内容）
5
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association
支持公平获取用于艾滋病毒预防和治疗的长效注射剂的政策建议：美国传染病学会与艾滋病毒医学协会的政策文件
Julia L Marcus and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 206–211, https://doi.org/10.1093/cid/ciae648
Voices of ID（传染病之声）
6
A “Terminal Infection”
“绝症感染”
Jennifer Furin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 212–214, https://doi.org/10.1093/cid/ciaf332
Invited Commentary（特邀评论）
7
A Rapid Test to Differentiate Viral From Bacterial Infections: Searching for the Holy Grail
区分病毒与细菌感染的快速检测：寻找“圣杯”
Lao-Tzu Allan-Blitz and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 215–218, https://doi.org/10.1093/cid/ciaf585
Bacterial Infections（细菌感染）
8
Nonoperative Versus Neurosurgical Treatment of Brain Abscess: An Emulated Trial Nested Within a Nationwide, Population-Based Cohort
脑脓肿的非手术治疗与神经外科治疗：一项基于全国人群队列的模拟试验
Emilie Marie Eriksen and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 219–227, https://doi.org/10.1093/cid/ciaf304
9
What Is the Impact of Anti-Enterococcal Empirical Therapy on Survival of Patients With Enterococcal Bloodstream Infections?
抗肠球菌经验性治疗对肠球菌血流感染患者生存率的影响是什么？
Linda Bussini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 228–237, https://doi.org/10.1093/cid/ciaf323
10
Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials
辅助使用磷霉素治疗金黄色葡萄球菌菌血症：两项随机试验个体参与者数据的汇总事后分析
Francesc Escrihuela-Vidal and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 238–245, https://doi.org/10.1093/cid/ciaf387
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
11
Kinetics of Non-nucleoside Reverse Transcriptase Inhibitor Resistance-associated Mutations in HIV-1 Proviral Cellular Reservoirs in Non-nucleoside Reverse Transcriptase Inhibitor-experienced Persons
在接受过非核苷类逆转录酶抑制剂治疗的HIV-1感染者中，非核苷类逆转录酶抑制剂耐药相关突变在HIV-1前病毒细胞储存库中的动力学
Thomas Drumel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 246–251, https://doi.org/10.1093/cid/ciaf430
12
Impact of Different Integrase Strand Transfer Inhibitors on Body Mass Index Among People With HIV Who Newly Started Antiretroviral Therapy in Shenzhen, China: A Real-World Data Analysis
中国深圳新开始抗逆转录病毒治疗的HIV感染者使用不同整合酶链转移抑制剂对体重指数的影响：一项现实数据分析
Lukun Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 252–261, https://doi.org/10.1093/cid/ciaf466
13
Consequences of Stopping Antiretroviral Treatment in a Persistently Seronegative Individual with HIV-1
HIV-1持续血清阴性个体停止抗逆转录病毒治疗的后果
Marc Wirden and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 262–264, https://doi.org/10.1093/cid/ciaf422
14
Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence
在成人HIV患病率最高的50个国家中，多替拉韦为基础的抗逆转录病毒治疗出现病毒学失败的治疗方法
Cameron T Nutt and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 265–273, https://doi.org/10.1093/cid/ciaf444
Mycobacterial Infections（结核分枝杆菌感染）
15
Retrospective Cohort Analysis for Identification of Discordant Rifampicin-resistant Xpert MTB/RIF Assay Results in South Kivu, Eastern Democratic Republic of the Congo, a High Burden Tuberculosis Setting
刚果民主共和国东部南基伍这一结核病高负荷地区，识别利福平耐药不一致的Xpert MTB/RIF检测结果的回顾性队列分析
Bertin C Bisimwa and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 274–281, https://doi.org/10.1093/cid/ciaf451
16
Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country
生物疗法治疗患者中结核病的预防：某低流行国家一个专科结核病诊所20年的经验
Sandra Pérez-Recio and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 282–290, https://doi.org/10.1093/cid/ciaf491
17
Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial
减少家庭内结核病传播：一项试点整群随机对照试验
Cinthya Ruiz-Tagle and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 291–298, https://doi.org/10.1093/cid/ciaf526
18
(Un)masking Tuberculosis
（揭开）结核病的“面具”
Joseph N Burzynski and Neil W Schluger
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 299–300, https://doi.org/10.1093/cid/ciaf528
19
Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM)
评估TB-LAM在无HIV儿童中诊断结核病的准确性和额外价值（AccuLAM）
Lucía CarratalàCastro and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 301–303, https://doi.org/10.1093/cid/ciaf525
Sexually Transmitted Infections（性传播感染）
20
Potential Impact of Doxycycline Post-exposure Prophylaxis Prescribing Strategies on Incidence of Bacterial Sexually Transmitted Infections
多西环素暴露后预防用药策略对细菌性性传播感染发病率的影响
Michael W Traeger and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 304–311, https://doi.org/10.1093/cid/ciad488
21
Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections
填补空白：多西环素预防细菌性性传播感染的最新进展
Aniruddha Hazra and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 312–320, https://doi.org/10.1093/cid/ciae062
22
Reported Neurologic Manifestations Among Persons With Syphilis by Stage of Infection—12 States, 2019–2022
2019-2022年12个州按感染阶段划分的梅毒患者报告的神经系统表现
Sarah B Wondmeneh and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 321–325, https://doi.org/10.1093/cid/ciaf015
Viral Infections（病毒性感染）
23
Investigating the Role of Cytomegalovirus as a Cause of Stillbirths and Child Deaths in Low- and Middle-Income Countries Through Postmortem Minimally Invasive Tissue Sampling
通过死后微创组织采样，调查巨细胞病毒在低收入和中等收入国家死胎和儿童死亡原因中的作用
Sithembiso Velaphi and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 326–336, https://doi.org/10.1093/cid/ciaf098
Photo Quiz（影像问答）
24
Bursting at the Seams
“撑破”
Maxwell Olenski and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 337–340, https://doi.org/10.1093/cid/ciaf488
Viral Infections（病毒性感染）
25
Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019–2021
2019-2021年巴基斯坦2型疫苗衍生脊髓灰质炎病毒疫情的临床和流行病学调查
Nayab Mehmood and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 341–351, https://doi.org/10.1093/cid/ciaf151
26
Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication
灭活脊髓灰质炎疫苗必须是根除脊髓灰质炎的重要组成部分
Konstantin Chumakov and Stanley A Plotkin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 352–353, https://doi.org/10.1093/cid/ciaf215
Photo Quiz（影像问答）
27
Intracranial Lesion in a Patient With Chronic Myeloid Leukemia
慢性髓性白血病患者颅内病变
Mohammed Shakeel Sillat and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 354–357, https://doi.org/10.1093/cid/ciaf441
Viral Infections（病毒性感染）
28
Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not Significantly Associated With Worse Clinical Outcomes Among Children Aged <2 Years: New Vaccine Surveillance Network, 2016–2020
在<2岁的婴幼儿中，呼吸道合胞病毒与其他呼吸道病毒共同检测与临床预后恶化无显著关联：2016-2020年新疫苗监测网络数据
Justin Z Amarin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 358–365, https://doi.org/10.1093/cid/ciaf194
29
Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection
一例异基因造血干细胞移植后严重、阿昔洛韦耐药的单纯疱疹病毒1型（HSV-1）感染患儿的HSV-1特异性T细胞的输注
Astrid Wintering and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 366–369, https://doi.org/10.1093/cid/ciaf125
Clinical Trials（临床实验）
30
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
干扰素-α鼻喷雾剂预防可降低癌症患者新冠病毒感染率：一项随机、双盲、安慰剂对照试验
Michelle K Yong and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e208–e216, https://doi.org/10.1093/cid/ciaf409
31
A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8
一项3期随机试验，调查V116（一种成人特异性肺炎球菌结合疫苗）在未接种过肺炎球菌疫苗且患肺炎球菌疾病风险增加的18-64岁年龄段成人中的安全性、耐受性和免疫原性，STRIDE-8试验
Paul T Scott and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e217–e226, https://doi.org/10.1093/cid/ciaf604
32
Effect of Direct-from-blood Bacterial Testing on Antibiotics Administration in Adults Presenting With Acute Infection: A Randomized Trial
直接从血液进行细菌检测对急性感染成年患者抗生素给药的影响：一项随机试验
David C Gaston and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e227–e235, https://doi.org/10.1093/cid/ciaf677
33
The Tantalizing Pursuit for a Perfect Diagnostic Test: Balancing Innovation With Stewardship
对完美诊断检测的诱人追求：平衡创新与管理
K C Coffey and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e236–e238, https://doi.org/10.1093/cid/ciaf674
Global Health and Neglected Tropical Diseases（全球健康与被忽视的热带病）
34
Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein
在一项前瞻性多国队列研究中，结核病筛查试验的诊断准确性：计算机辅助检测的胸部X光片、Xpert结核宿主反应检测和C反应蛋白
Rebecca Crowder and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e239–e247, https://doi.org/10.1093/cid/ciae549
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
35
Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2
通过PCE、PREVENT和SCORE2对全球心血管疾病预防队列中艾滋病毒感染者进行风险评估
Steven K Grinspoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e248–e257, https://doi.org/10.1093/cid/ciaf542
36
REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks
HIV新心血管风险计算器的REPRIEVE分析：低估风险意味着预防的心脏病发作更少
Matthew S Durstenfeld
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e258–e261, https://doi.org/10.1093/cid/ciaf543
37
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)
在病毒学抑制的HIV感染成人中，转换为比克替拉韦/恩曲他滨/丙酚替诺福韦与继续使用多替拉韦/拉米夫定后的炎症和代谢结局相当（INSTINCT/GESIDA10918研究）
Sergio Serrano-Villar and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e262–e274, https://doi.org/10.1093/cid/ciaf565
38
Tenofovir Alafenamide and Body Weight: Have We Finally Tipped the Scale?
丙酚替诺福韦与体重：我们最终是否打破了平衡？
John R Koethe
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e275–e277, https://doi.org/10.1093/cid/ciaf566
39
Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study
在Tatelo研究中，接受VRC01LS和10-1074单克隆抗体治疗的儿童的长期临床、免疫学和病毒储存库结局
Gbolahan Ajibola and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e278–e285, https://doi.org/10.1093/cid/ciaf568
40
Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015–2023
2015-2023年美国开具HIV暴露后预防处方的患者趋势
John N Le and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e286–e295, https://doi.org/10.1093/cid/ciaf581
Immunocompromised Hosts（免疫功能低下宿主）
41
Epidemiology, Risk Factors, and Outcomes of Neutropenic Enterocolitis in Onco-Hematological Patients According to Chemotherapy Regimen
根据化疗方案分析肿瘤血液学患者中性粒细胞减少性肠结肠炎的流行病学、危险因素和预后
Anne-Sophie Brunel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e296–e307, https://doi.org/10.1093/cid/ciaf134
42
An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant
在一项3期随机、安慰剂对照试验中，分析来特莫韦预防对巨细胞病毒血清阳性异基因造血细胞移植受者巨细胞病毒特异性细胞介导免疫的影响
Genovefa A Papanicolaou and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e308–e315, https://doi.org/10.1093/cid/ciaf646
43
Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients
在供体巨细胞病毒血清阳性/受体巨细胞病毒血清阴性的肾移植受者中，来特莫韦与缬更昔洛韦预防的3期试验中，巨细胞病毒（CMV）特异性细胞介导免疫对预防后CMV疾病的预测作用
Ajit P Limaye and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e316–e324, https://doi.org/10.1093/cid/ciaf632
44
The Role of Cytomegalovirus-Specific Cellular Immunity in Transplant Recipients with Letermovir Prophylaxis: To be Determined
来特莫韦预防移植受者中巨细胞病毒特异性细胞免疫的作用：有待确定
Yoichiro Natori and Martina Sester
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e325–e327, https://doi.org/10.1093/cid/ciaf633
45
IL12RB1 Deficiency Appearing in North America: Expanding the Clinical Phenotypes
北美出现的IL12RB1缺陷：拓展临床表型
Chen Wang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e328–e331, https://doi.org/10.1093/cid/ciaf637
Vaccines（疫苗）
46
A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017
一项评估人乳头瘤病毒9vHPV疫苗在感染HIV的男男性行为者中免疫原性的IV期、开放标签、单臂、多中心临床试验：GeSIDA 10 017研究
Raquel Ron and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e332–e342, https://doi.org/10.1093/cid/ciaf435
47
Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines
与流感疫苗和23价肺炎球菌多糖疫苗同时接种的COVID-19信使核糖核酸疫苗的免疫原性和安全性
Omid Rezahosseini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e343–e351, https://doi.org/10.1093/cid/ciaf455
48
Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns
健康新生儿对新型2型口服脊髓灰质炎疫苗的肠道黏膜免疫反应
Audrey Godin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e352–e360, https://doi.org/10.1093/cid/ciaf484
49
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season
老年人呼吸道合胞病毒相关急性呼吸道疾病的估计疫苗有效性：首个上市后季节的研究结果
Sara Y Tartof and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e361–e370, https://doi.org/10.1093/cid/ciaf496
Sexually Transmitted Infections（性传播感染）
50
Systematic Review and Meta-analysis of the Association Between Mycoplasma genitalium and Pelvic Inflammatory Disease (PID)
生殖支原体与盆腔炎性疾病（PID）关联的系统综述和荟萃分析
Kay Htaik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e371–e379, https://doi.org/10.1093/cid/ciae295
51
Sexually Transmitted Infection (STI)/HIV Testing, STIs, and HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men and Men Who Have Sex With Men and Women in the United States, 2019–2022
2019-2022年美国男男性行为者以及男男性行为者和女性性行为者中性传播感染（STI）/HIV检测、性传播感染和HIV暴露前预防用药情况
Guoyu Tao and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e380–e386, https://doi.org/10.1093/cid/ciae314
52
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083
卡博特韦在细菌性性传播感染情况下维持保护效力：HPTN 083的二次分析
Meredith E Clement and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e387–e395, https://doi.org/10.1093/cid/ciae572
Viral Infections（病毒性感染）
53
Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized With Respiratory Syncytial Virus
对因呼吸道合胞病毒感染住院患者的心血管事件和危险因素的综合分析
Paulina Sudnik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e396–e403, https://doi.org/10.1093/cid/ciaf310
54
In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines
处于危急状况：迫切需要支持猴痘治疗和诊断管线
Carmen Perez Casas and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e404–e408, https://doi.org/10.1093/cid/ciaf529
Correspondence（读者来信）
55
Caution in Interpreting INSTIs and Weight in Observational Studies
在观察性研究中解读整合酶抑制剂与体重关系时需谨慎
Esteban Martínez
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page e409, https://doi.org/10.1093/cid/ciaf569
56
Weight Trajectories With Integrase Inhibitors: Unaddressed Insights and Limitations in a Chinese Cohort
整合酶抑制剂与体重变化轨迹：中国队列中未解决的见解和局限性
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e409–e410, https://doi.org/10.1093/cid/ciaf570
57
Real-World Evidence as a Complement to Randomized Trials in Interpreting Weight Gain on Modern INSTI Regimens
现实证据作为随机试验的补充，用于解读现代整合酶抑制剂方案导致的体重增加
Xinsheng Wu and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e410–e411, https://doi.org/10.1093/cid/ciaf571
58
C-reactive Protein in TB Meningitis: Signal, Surrogate, or Saboteur?
结核性脑膜炎中的C反应蛋白：信号、替代指标还是破坏因素？
Patrick K Moonan and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e411–e412, https://doi.org/10.1093/cid/ciaf575
59
C-Reactive Protein in Tuberculous Meningitis: A Viable Biomarker for Individualized Care
结核性脑膜炎中的C反应蛋白：个体化护理的可行生物标志物
Lillian Tugume and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e412–e413, https://doi.org/10.1093/cid/ciaf576
60
The Win Ratio Should Be Complemented by Other Win Statistics to Provide a Comprehensive Picture of Relative and Absolute Treatment Effects: The Case Study of the REPRIEVE Trial
胜利比率应与其他胜利统计数据相结合，以全面呈现相对和绝对治疗效果：REPRIEVE试验案例研究
Melissa J Hardy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e413–e414, https://doi.org/10.1093/cid/ciaf587
61
Small Effects, Big Impact: Multiple Win Measures Aid Interpretation, But Do Not Forget the Bigger Picture
效应虽小，影响重大：多种胜利衡量指标有助于解读，但不要忘记整体情况
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e414–e416, https://doi.org/10.1093/cid/ciaf588
62
Does Oral Antibiotic Switching Therapy Show Similar Efficacy to Intravenous Administration for Treating Infective Endocarditis?
口服抗生素转换疗法治疗感染性心内膜炎的疗效是否与静脉给药相似？
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e416–e417, https://doi.org/10.1093/cid/ciaf598
63
Toward a Wider Use of Oral Antibiotic Switch in Infective Endocarditis
朝着更广泛地使用感染性心内膜炎口服抗生素转换疗法迈进
Romane Pouy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e417–e418, https://doi.org/10.1093/cid/ciaf599
64
Operationalizing Sepsis Definitions With Artificial Intelligence: Toward Smarter Antibiotic Use
利用人工智能实现败血症定义的落地应用：迈向更明智的抗生素使用
James S Ford and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e418–e419, https://doi.org/10.1093/cid/ciaf601
65
Balancing Innovation in Artificial Intelligence With Practical Sepsis Definitions
平衡人工智能创新与实用的败血症定义
Chanu Rhee and Michael Klompas
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e419–e420, https://doi.org/10.1093/cid/ciaf602
66
Precision Prevention of Tuberculosis in Biologic Therapy: Lessons Beyond Screening Strategies
生物疗法中结核病的精准预防：筛查策略之外的启示
Shiuan-Chih Chen and Yuan-Ti Lee
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e420–e421, https://doi.org/10.1093/cid/ciaf559
67
Recalibrating COVID-19 Booster Policy: Lessons From Hybrid Immunity and Global Equity Gaps
重新调整COVID-19加强针政策：从混合免疫和全球公平差距中吸取教训
Nathkapach K Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e421–e422, https://doi.org/10.1093/cid/ciaf605
Clinical Infectious Diseases Volume 82 Issue 3
临床传染病学 82卷 3期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Dracunculiasis, 1674
1674年的麦地那龙线虫病
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page i, https://doi.org/10.1093/cid/ciag089
In the Literature（文献聚焦）
2
In the Literature
文献聚焦
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages ii–iv, https://doi.org/10.1093/cid/ciag012
State-of-the-Art Review（前沿综述）
3
State-of-the-Art Review: Managing Vulvovaginal Candidiasis
前沿综述：外阴阴道念珠菌病的治疗
Riina Rautemaa-Richardson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 371–382, https://doi.org/10.1093/cid/ciaf673
Ethics Rounds（伦理探讨）
4
CARB Your Enthusiasm: An Ethics-Informed Analysis for Clinicians of the US National Action Plan for Combating Antibiotic-Resistant Bacteria
谨慎对待抗生素：基于伦理学分析美国国家抗耐药菌行动计划对临床医生的启示
Hunter Jackson Smith and Chelsea Modlin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 383–388, https://doi.org/10.1093/cid/ciaf478
Voices of ID（传染病之声）
5
Mothers
母亲们
Maria Koshy
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 389–390, https://doi.org/10.1093/cid/ciaf338
Bacterial Infections（细菌性感染）
6
The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens
多粘菌素与美罗培南联合治疗对碳青霉烯类耐药革兰氏阴性菌所致肺炎或血行感染患者预后的影响
Mariya Huralska and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 391–398, https://doi.org/10.1093/cid/ciaf398
7
We Cannot Overcome the Mediocrity of Colistin
我们无法忽视多粘菌素的平庸疗效
Jason C Gallagher
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 399–401, https://doi.org/10.1093/cid/ciaf592
8
Comparing Clinical, Microbiological, and Genetic Definitions of Relapse in Patients With Subsequent Episodes of Methicillin-resistant Staphylococcus aureus Bone and Joint Infection
比较耐甲氧西林金黄色葡萄球菌骨关节感染后续发作患者复发在临床、微生物学和遗传学上的定义
Kevin Bouiller and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 402–410, https://doi.org/10.1093/cid/ciaf448
9
Non-Klebsiella pneumoniae Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia Complex, Stenotrophomonas maltophilia, and Acinetobacter baumannii
新型β-内酰胺/β-内酰胺酶抑制剂对非肺炎克雷伯菌碳青霉烯酶的抗菌特性，第二部分：洋葱伯克霍尔德菌复合群、嗜麦芽窄食单胞菌和鲍曼不动杆菌
Andrew J Fratoni and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 411–419, https://doi.org/10.1093/cid/ciaf403
Clinical Trials（临床试验）
10
Continuation Versus Temporary Interruption of Immunomodulatory Agents During Infections in Patients With Inflammatory Rheumatic Diseases: A Randomized Controlled Trial
炎症性风湿性疾病患者感染期间继续使用与暂时停用免疫调节剂的随机对照试验
Merel A A Opdam and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 420–426, https://doi.org/10.1093/cid/ciaf442
11
Effectiveness of Nebulized Bronchodilator-Enhanced Sputum Induction in Thai Patients With Presumed Pulmonary Tuberculosis: A Randomized Controlled Trial (NeB-TB Trial)
泰国疑似肺结核患者中雾化支气管扩张剂增强痰诱导的有效性：一项随机对照试验（NeB-TB试验）
Pichanon Mingchay and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 427–435, https://doi.org/10.1093/cid/ciaf580
12
Bone Biopsy not Superior to Ulcer Bed Biopsy–guided Antibacterial Therapy on Remission of Diabetic Foot Osteomyelitis: A Randomized Controlled Trial
在指导用于缓解糖尿病足骨髓炎的抗菌治疗方面骨活检并不优于溃疡床活检：一项随机对照试验
Rimke S Lagrand and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 436–442, https://doi.org/10.1093/cid/ciaf684
13
Do We Need a Bone Biopsy for Managing Diabetic Foot Osteomyelitis?
我们是否需要对糖尿病足骨髓炎进行骨活检？
Eric M Senneville and Benjamin A Lipsky
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 443–445, https://doi.org/10.1093/cid/ciaf685
Critical Care and Sepsis（重症监护与败血症）
14
Contamination of Blood Cultures Drawn From Arterial Catheters Versus Venipuncture or Venous Catheters in Critically Ill Patients: A Systematic Review and Meta-analysis
危重患者从动脉导管与静脉穿刺或静脉导管采集血培养的污染情况：一项系统综述和荟萃分析
Takatoshi Koroki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 446–452, https://doi.org/10.1093/cid/ciaf260
15
Reassessing Procalcitonin-Guided Antibiotic Therapy in Critically Ill Patients With Sepsis: Lessons From the ADAPT-Sepsis Trial
重新评估降钙素原指导的败血症危重患者抗生素治疗：来自ADAPT-败血症试验的启示
Simran Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 453–458, https://doi.org/10.1093/cid/ciaf336
Infection Control and Hospital Epidemiology（传染病控制与医院流行病学）
16
Effectiveness and Safety of Methods to Prevent Bloodstream and Other Infections and Noninfectious Complications Associated With Peripherally Inserted Central Catheters: A Systematic Review and Meta-Analysis
预防经外周静脉置入中心静脉导管相关血行感染及其他感染和非感染性并发症的方法的有效性和安全性：一项系统综述和荟萃分析
Andreea Dobrescu and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 459–472, https://doi.org/10.1093/cid/ciaf063
17
Using Generative Artificial Intelligence for Healthcare-Associated Infection Surveillance
利用生成式人工智能进行医院感染监测
Daniel J Morgan and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 473–479, https://doi.org/10.1093/cid/ciaf619
18
Artificial Intelligence and the Future of Healthcare-Associated Infection Surveillance: Bridging Precision, Partnership, Practice, and People
人工智能与医院感染监测的未来：融合精准、合作、实践与人文
Mamdooh Alzyood
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 480–483, https://doi.org/10.1093/cid/ciaf620
Infections in Older Adults（老年传染病学）
19
Evaluation of Influenza Antiviral Prophylaxis for Long-term Care Residents: A Systematic Review and Meta-Analysis
长期护理机构居民流感抗病毒预防的效果评价：一项系统综述和荟萃分析
Ryan Hanula and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 484–493, https://doi.org/10.1093/cid/ciaf101
20
Implementation of Diagnostic Stewardship to Improve Urinary Tract Infection Antibiotic Use Across 3 Medical Centers
在三家医疗中心实施诊断管理以改善尿路感染抗生素的使用
Kimberly C Claeys and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 494–500, https://doi.org/10.1093/cid/ciaf411
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
21
Adverse Events of First-Line Therapy for Pediatric Tuberculosis: A Systematic Review and Meta-Analysis
儿童结核病一线治疗的不良反应：一项系统综述和荟萃分析
Michael Prodanuk and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 501–512, https://doi.org/10.1093/cid/ciaf152
22
The Impact of Pregnancy on Tuberculosis Treatment Outcomes: An Analysis of Brazilian National Surveillance Data 2016–2022
妊娠对结核病治疗效果的影响：基于2016-2022年巴西国家监测数据的分析
Silvia S Chiang and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 513–521, https://doi.org/10.1093/cid/ciaf233
Photo Quiz（影像问答）
23
Persistent Fever and Back Pain After Liver Transplantation
肝移植后持续发热和背痛
Toshiyuki Kishida and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 522–525, https://doi.org/10.1093/cid/ciaf489
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
24
Stool Processing Methods for Xpert Ultra Testing in Childhood Tuberculosis: A Prospective, Multicountry Accuracy Study
儿童结核病Xpert Ultra检测的粪便处理方法：一项前瞻性、多国准确性研究
Devan Jaganath and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 526–534, https://doi.org/10.1093/cid/ciaf289
Photo Quiz（影像问答）
25
A Bloom Beneath the Skin
皮下绽放之花
Yi Rong Chew and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 535–538, https://doi.org/10.1093/cid/ciaf550
Vector-Borne Diseases（虫媒传染病）
26
Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data, and Outcomes
过去十年无形体病趋势：临床特征、实验室数据和预后回顾
Silpita Katragadda and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 539–547, https://doi.org/10.1093/cid/ciaf171
27
Completion of Paired Serological Testing Algorithms for Spotted Fever Rickettsiosis and Ehrlichiosis, North Carolina: 2017–2020
斑点热立克次体病和埃里希体病配对血清学检测算法的完成情况，北卡罗来纳州：2017-2020年
Huipeng Liao and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 548–555, https://doi.org/10.1093/cid/ciaf176
COVID-19/SARS-COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
28
Effect of Metformin on the Risk of Post-COVID-19 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study
二甲双胍对超重或肥胖人群患新冠后综合征风险的影响：一项基于人群的回顾性队列研究
Ubonphan Chaichana and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e423–e432, https://doi.org/10.1093/cid/ciaf429
29
Preventing Long COVID With Metformin
使用二甲双胍预防新冠长期症状
Carolyn T Bramante and David R Boulware
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e433–e435, https://doi.org/10.1093/cid/ciaf700
30
Effectiveness of COVID-19 Vaccination and Prior Infections to Reduce Long COVID Risk During the Pre-Omicron and Omicron Periods
COVID-19疫苗接种和既往感染在奥密克戎变异株出现前及奥密克戎时期降低新冠长期症状风险的有效性
Sara Carazo and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e436–e445, https://doi.org/10.1093/cid/ciaf549
31
International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness
国际合作制定并统一新冠期间奈玛特韦/利托那韦药物相互作用指南：为未来大流行准备汲取的经验教训
Safia Kuriakose and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e446–e454, https://doi.org/10.1093/cid/ciaf606
Endovascular Infections（血管内感染）
32
Antifungal Therapy in Candida Infective Endocarditis: A Comparison of Echinocandins and Other Treatment Regimens in a Nationwide Cohort Study
念珠菌感染性心内膜炎的抗真菌治疗：一项全国队列研究中棘白菌素与其他治疗方案比较
Siri Kurland and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e455–e461, https://doi.org/10.1093/cid/ciaf312
33
Should We Extend the Use of Oral Antibiotics in Infective Endocarditis? The ENDO-ORAL Study
我们是否应延长感染性心内膜炎口服抗生素的使用？ENDO-ORAL研究
Benoit Rallet and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e462–e470, https://doi.org/10.1093/cid/ciaf452
34
Rethinking the Routine: Are Repeat Blood Cultures Necessary After Completion of Infective Endocarditis Treatment?
重新思考常规做法：感染性心内膜炎治疗完成后是否需要重复血培养？
Jean Regina and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e471–e474, https://doi.org/10.1093/cid/ciaf617
35
Posttreatment Blood Cultures in Patients With Infective Endocarditis: Valuable, Inconsequential, or Worse?
感染性心内膜炎患者治疗后的血培养：有价值、无关紧要还是有害？
Daniel C DeSimone and Larry M Baddour
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e475–e476, https://doi.org/10.1093/cid/ciaf618
Fungal Infections（真菌感染）
36
Fungal Meningitis in US Patients Who Received Epidural Anesthesia in Matamoros, Mexico
在墨西哥马塔莫罗斯接受硬膜外麻醉的美国患者中的真菌性脑膜炎
Dallas J Smith and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e477–e484, https://doi.org/10.1093/cid/ciaf399
37
Empirical Antifungal Treatment of Critically ⅢPatients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study
流感相关急性呼吸窘迫综合征危重患者的经验性抗真菌治疗：一项倾向评分加权观察性研究
Stefan Hatzl and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e485–e493, https://doi.org/10.1093/cid/ciaf507
38
Is Empirical Antifungal Therapy the Next Path Forward in Patients With Influenza-Associated ARDS?
经验性抗真菌治疗是否是流感相关急性呼吸窘迫综合征患者的下一步治疗方向？
Florian Reizine and Jean-Pierre Gangneux
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e494–e496, https://doi.org/10.1093/cid/ciaf508
39
Valley Fever in Central California: Diagnosis is Not the Finish Line, the Real Gap is Longitudinal Care
加利福尼亚州中部山谷热：诊断并非终点，真正的差距在于纵向护理
Geetha Sivasubramanian
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e497–e502, https://doi.org/10.1093/cid/ciaf728
Hepatitis（肝炎）
40
The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia
澳大利亚接受阿片类激动剂治疗者的丙型肝炎治疗流程
Samara Griffin and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e503–e510, https://doi.org/10.1093/cid/ciaf352
41
Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002–2023)
西班牙20多年来（2002-2023年）HIV感染者中丙型肝炎病毒感染流行率的趋势
Juan Berenguer and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e511–e520, https://doi.org/10.1093/cid/ciaf407
42
Gaps in the Hepatitis C Prenatal and Postpartum Care Cascade: Rationale for Treatment in Pregnancy
丙型肝炎围产期和产后治疗流程中的差距：孕期治疗的理由
Andrew B Mendlowitz and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e521–e533, https://doi.org/10.1093/cid/ciaf578
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
43
Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series
艾巴利珠单抗和来那卡帕韦联合治疗多重耐药HIV-1：病例系列研究
Charlotte Rolle and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e534–e540, https://doi.org/10.1093/cid/ciaf597
44
New Strategies for a Vexing Problem: Injectables to the Rescue for People With Multidrug-Resistant HIV
棘手问题的新策略：注射剂助力多重耐药HIV感染者
William R Short and Onyema E Ogbuagu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e541–e543, https://doi.org/10.1093/cid/ciaf600
45
The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV
反弹效应：HIV感染者停用低剂量司美格鲁肽后会发生什么
Kristine M Erlandson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e544–e548, https://doi.org/10.1093/cid/ciaf652
46
Infections After Kidney Transplantation From Donors With HIV to Recipients With HIV
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况
Elizabeth C Arant and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e549–e557, https://doi.org/10.1093/cid/ciaf656
47
Infections After Kidney Transplantation from Donors with HIV to Recipients with HIV: Insights, Prevention, and the Path Forward
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况：见解、预防和未来方向
Abhay Dhand and Stephanie M Pouch
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e558–e560, https://doi.org/10.1093/cid/ciaf657
Respiratory Infections（呼吸道传染病）
48
Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus
成人呼吸道合胞病毒感染的多病共存情况及严重院内结局
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e561–e570, https://doi.org/10.1093/cid/ciaf405
49
Characterizing Treatment Adherence Trajectories in the endTB Multisite Cohort of Drug-Resistant Tuberculosis Patients: An Application of Group-Based Trajectory Modeling
在endTB多站点耐药结核病患者队列中描述治疗依从性轨迹：基于组别的轨迹建模应用
Stephanie Law and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e571–e579, https://doi.org/10.1093/cid/ciaf467
50
Severity of Clinical Presentation and Outcomes in Hospitalized Adult People With Influenza by Type and Subtype, United States—2017–2020
2017 - 2020年美国按流感类型和亚型划分的住院成人流感患者临床表现严重程度及预后
Seana Cleary and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e580–e588, https://doi.org/10.1093/cid/ciaf545
51
Reported Tuberculosis Symptoms: An Inadequate Classifier of Disease State
报告的结核病症状：疾病状态分类的不足指标
Nicky McCreesh and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e589–e594, https://doi.org/10.1093/cid/ciaf611
Sexually Transmitted Infections（性传播感染）
52
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024
2023 - 2024年更新版（单价XBB.1.5）新冠疫苗对SARS-CoV-2奥密克戎XBB和BA.2.86/JN.1谱系住院的有效性及临床严重程度比较——IVY网络，26家医院，2023年10月18日 - 2024年3月9日
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e595–e603, https://doi.org/10.1093/cid/ciae405
53
High Prevalence of Haemophilus ducreyi Among Patients With Suspected Primary syphilis in Malawi, 2019–2022
2019 - 2022年马拉维疑似原发性梅毒患者中杜克雷嗜血杆菌的高流行率
Mitch M Matoga and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e604–e611, https://doi.org/10.1093/cid/ciaf114
54
Characteristics Associated With Disseminated Gonococcal Infections vs Uncomplicated Gonorrhea: A California Case-control Study, 2021–2022
与播散性淋球菌感染（而非单纯性淋病）相关的特征：2021 - 2022年加利福尼亚病例对照研究
Kelly A Johnson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e612–e615, https://doi.org/10.1093/cid/ciaf311
Viral Infections（病毒性感染）
55
Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men
男男性行为者肛门人乳头瘤病毒感染进展为疾病的情况
Joel M Palefsky and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e616–e625, https://doi.org/10.1093/cid/ciaf584
Correspondence（读者来信）
56
Cardiac Complications of Mycoplasma pneumoniae: Overlooked Confounders, Biomarkers, and Host-Driven Shifts
肺炎支原体感染的心脏并发症：被忽视的混杂因素、生物标志物及宿主驱动的变化
Shiuan-Chih Chen and Ming-Cheng Lin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e626–e627, https://doi.org/10.1093/cid/ciaf609
57
Mycoplasma pneumoniae–Associated Cardiac Complications Revisited
重新审视肺炎支原体相关心脏并发症
Daniel Grupel and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e627–e628, https://doi.org/10.1093/cid/ciaf610
58
Screening for Anal Cancer Is Associated With Real Harms and Questionable Benefits
肛门癌筛查存在实际危害且益处存疑
Chris Kenyon
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e628, https://doi.org/10.1093/cid/ciaf613
59
Anal Cancer Screening: A Balanced Approach is Necessary
肛门癌筛查：需采取平衡的方法
Hayden S Andrews and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e628–e629, https://doi.org/10.1093/cid/ciaf614
60
Collateral Benefits and Methodological Limits of Respiratory Syncytial Virus Immunization for Infant Otitis Media and Antibiotic Use
呼吸道合胞病毒免疫接种对婴儿中耳炎和抗生素使用的附带益处及方法学局限
Tsai Ling Ting and Kai-Lun Sheu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e629–e630, https://doi.org/10.1093/cid/ciaf640
61
Interpretation of Respiratory Syncytial Virus Immunization Impact on Pediatric Acute Otitis Media: Key Considerations
解读呼吸道合胞病毒免疫接种对儿童急性中耳炎的影响：关键考量因素
Inès Fafi and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e630–e631, https://doi.org/10.1093/cid/ciaf641
62
A Possible Increase in Penicillin-Resistant Strains of Treponema pallidum
梅毒螺旋体青霉素耐药菌株可能增加
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e631–e632, https://doi.org/10.1093/cid/ciaf643
63
Surveillance of Resistance-Associated Mutations in Treponema pallidum
梅毒螺旋体耐药相关突变的监测
Kai-Hsiang Chen and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e632–e633, https://doi.org/10.1093/cid/ciaf645
64
Does Empirical Antifungal Therapy Reduce IAPA in Influenza-Associated ARDS? Methodological Concerns on Diagnosis, Surveillance, and Clinical Heterogeneity
经验性抗真菌治疗能否减少流感相关急性呼吸窘迫综合征（IAPA）的发生？诊断、监测和临床异质性方面的方法学问题
Ming Xue and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e633–e634, https://doi.org/10.1093/cid/ciaf661
65
Empirical Antifungal Therapy and IAPA in Influenza-Associated ARDS: Insights from Real-World Data
流感相关急性呼吸窘迫综合征中的经验性抗真菌治疗和IAPA：来自现实数据的见解
Stefan Hatzl and Robert Krause
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e634, https://doi.org/10.1093/cid/ciaf664
Clinical Infectious Diseases Volume 82 Issue Supplement_2
临床传染病学 82卷 增刊2期
https://academic.oup.com/cid/issue/82/Supplement_2
SUPPLEMENT（增刊）
Advancing Tuberculosis Research Through RePORT International: Enhancing Treatment Outcomes, Predicting Disease Progression, and Improving Diagnosis
通过结核病区域性前瞻性观察研究国际联盟（RePORT International）推动结核病研究：提高治疗效果、预测疾病进展及改善诊断
SUPPLEMENT ARTICLES（增补论著）
1
A Narrative Review of the Regional Prospective Observational Research in Tuberculosis International Consortium: Sharing Diverse Data and Specimens in the Fight Against Tuberculosis
结核病区域性前瞻性观察研究国际联盟的叙述性综述：在抗击结核病中共享多样数据和样本
Rajita Bhavaraju and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S53–S59, https://doi.org/10.1093/cid/ciag151
2
Long-term Sequelae of Pulmonary Tuberculosis: A Narrative Review
长期肺部结核后遗症：一项叙述性综述
Akshay N Gupte and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S60–S67, https://doi.org/10.1093/cid/ciag123
3
From Exposure to Disease: Predicting Tuberculosis Progression
从接触感染到发病：预测结核病进展
Mariana Araújo-Pereira and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S68–S74, https://doi.org/10.1093/cid/ciag125
4
Asymptomatic Tuberculosis Across the Disease Spectrum: A Scoping Review of Epidemiology, Diagnosis, and Public Health Implications
疾病谱中的无症状结核：一项关于流行病学、诊断和公共卫生影响的范围综述
Beatriz Barreto Duarte and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S75–S84, https://doi.org/10.1093/cid/ciag150
Clinical Infectious Diseases Volume 82 Issue 4
临床传染病学 82卷 4期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时光的传染病学技艺）
1
La Petite Vérole
天花
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page i, https://doi.org/10.1093/cid/ciag118
In the Literature（文献精选）
2
In the Literature
文献精选
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag013
Joint Editorial（联合社论）
3
Protocols for Randomized Controlled Trials: Advancing Transparency in Infectious Diseases
随机对照试验方案：推动传染病领域透明度提升
Jean-Jacques Parienti and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page 557, https://doi.org/10.1093/cid/ciag198
Clinical Dilemmas in Infectious Diseases（临床传染病疑难杂症）
4
Uncertain Terrain
不确定的领域
Kap Sum Foong and Sara W Dong
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 558–561, https://doi.org/10.1093/cid/ciaf283
Voices of ID（传染病之声）
5
Lessons I Learned from Our Soldier
我从我们的士兵身上学到的经验
Mitchell J Schwaber
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 562–563, https://doi.org/10.1093/cid/ciaf433
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
6
Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South
美国南部城市由瑞安·怀特资助的诊所中，HIV-1病毒血症患者使用长效卡博特韦/利匹韦林、来那卡帕韦和艾巴利珠单抗的情况
Jonathan A Colasanti and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 564–574, https://doi.org/10.1093/cid/ciaf425
7
In the Mismatch: Viral Suppression Despite Low Tenofovir-Diphosphate in Dried Blood Spots in the Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort
矛盾现象：在多中心艾滋病队列研究/妇女跨机构HIV研究联合队列中，尽管干燥血斑中磷酸替诺福韦水平低，但仍能实现病毒抑制
Sarah C Mann and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 575–582, https://doi.org/10.1093/cid/ciaf509
8
Prognostic Value of Blood Epigenetic Biomarkers of Aging in Persons With Well-Controlled HIV-1 Infection
血液衰老表观遗传生物标志物在HIV-1感染控制良好人群中的预后价值
Patricia Martínez-Martín and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 583–591, https://doi.org/10.1093/cid/ciaf537
9
HIV Resistance to Dolutegravir Varies With Coadministered Agents
HIV对多替拉韦的耐药性随联合用药的不同而有所差异
Ingrid A Beck and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 592–596, https://doi.org/10.1093/cid/ciaf481
Immunocompromised Hosts（免疫功能低下宿主）
10
Letermovir Prophylaxis Guided by Cytomegalovirus Cell-Mediated Immunity Improves the Outcomes of Allogeneic Hematopoietic Stem Cell Transplant Recipients
基于巨细胞病毒细胞介导免疫的莱特莫韦预防可改善异体基因造血干细胞移植受者的预后
Luxiang Wang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 597–606, https://doi.org/10.1093/cid/ciaf410
11
Changing Clinical and Laboratory Characteristics of Progressive Multifocal Leukoencephalopathy: A Retrospective National Cohort Study
进行性多灶性白质脑病临床和实验室特征的变化：一项回顾性全国队列研究
Ilaria Mainardi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 607–617, https://doi.org/10.1093/cid/ciaf501
12
Respiratory Syncytial Virus After Chimeric Antigen Receptor T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort
嵌合抗原受体T细胞疗法后呼吸道合胞病毒感染：一项多中心回顾性队列研究中的风险因素和预后
Maria Isabel Sotelo-Alva and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 618–621, https://doi.org/10.1093/cid/ciag052
Respiratory Infections（呼吸道感染）
13
Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Community-Acquired Pneumonia Guidelines 2025 Update
美国传染病学会（IDSA）立场声明：为何IDSA未认可《2025年社区获得性肺炎指南》更新版
Michael Klompas and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 622–624, https://doi.org/10.1093/cid/ciaf625
14
We Dissent: Lessons From the 2025 Community-Acquired Pneumonia Guidelines
我们持不同意见：从《2025年社区获得性肺炎指南》中汲取的教训
Leila S Hojat and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 625–629, https://doi.org/10.1093/cid/ciaf626
15
Associations Between Antibiotic Use and Outcomes in Patients Hospitalized With Community-Acquired Pneumonia and Positive Respiratory Viral Assays
社区获得性肺炎且呼吸道病毒检测呈阳性住院患者抗生素使用与预后的关联
Brett Biebelberg and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 630–638, https://doi.org/10.1093/cid/ciaf687
16
Comparative Effectiveness of Azithromycin Versus Doxycycline in Hospitalized Patients With Community-Acquired Pneumonia Treated With Beta-Lactams: A Multicenter Matched Cohort Study
联合β-内酰胺类药物治疗社区获得性肺炎的住院患者中，阿奇霉素与多西环素疗效的比较：一项多中心匹配队列研究
Yewande E Odeyemi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 639–647, https://doi.org/10.1093/cid/ciaf252
17
Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia
针对中度免疫功能低下肺炎住院患者，经验性抗生素对临床预后的目标试验模拟研究
Louis Saravolatz and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 648–657, https://doi.org/10.1093/cid/ciaf344
18
Impact of Respiratory Syncytial Virus Immunization on the Rate of Pediatric Acute Otitis Media: A Time-series Analysis
呼吸道合胞病毒免疫接种对儿童急性中耳炎发生率的影响：一项时间序列分析
Inès Fafi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 658–664, https://doi.org/10.1093/cid/ciaf564
Vaccines（疫苗）
19
LC16m8 for Pre-exposure Prophylaxis Against Mpox in a High-Risk Population: An Open-Label Randomized Trial
使用LC16m8针对高危人群进行猴痘暴露前预防：一项开放标签随机试验
Nobumasa Okumura and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 665–672, https://doi.org/10.1093/cid/ciaf074
20
Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial
在感染人类免疫缺陷病毒的女性中，接种2剂与3剂九价人乳头瘤病毒疫苗的免疫原性和安全性：Papillon随机试验
Deborah Konopnicki and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 673–681, https://doi.org/10.1093/cid/ciaf241
21
Screening and Vaccination Rates for Tetanus, Hepatitis A, and Hepatitis B Among Individuals With Substance Use Disorders Hospitalized in an Integrated US Health System
在美国综合医疗机构中住院的成瘾性患者的破伤风、甲型肝炎和乙型肝炎筛查及接种率
Jennifer H Ku and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 682–688, https://doi.org/10.1093/cid/ciaf251
22
Atrial Fibrillation After Respiratory Syncytial Virus Vaccination Among Older Adults
老年人接种呼吸道合胞病毒疫苗后发生心房颤动的情况
Morgan Birabaharan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 689–691, https://doi.org/10.1093/cid/ciae649
23
Approaches to Comparing Influenza Vaccine Effectiveness to Guide Potential Preferential Product Recommendations
比较流感疫苗有效性的方法，以指导可能的优先产品推荐
Edward A Belongia and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 692–697, https://doi.org/10.1093/cid/ciaf563
Viral Infections（病毒性感染）
24
Clinical Features and Outcomes of Human Herpesvirus-6 DNAemia in Critically Ill Patients: A Retrospective Multicenter Analysis
危重患者人类疱疹病毒6型DNA血症的临床特征和预后：一项回顾性多中心分析
Margot Combet and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 698–708, https://doi.org/10.1093/cid/ciaf199
25
Kaposi Sarcoma–Associated Herpesvirus Risk and Disease in Kidney Donors and Transplant Recipients With HIV in the United States
美国HIV感染肾捐赠者和移植受者中卡波西肉瘤相关疱疹病毒的风险和疾病
Puja H Nambiar and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 709–719, https://doi.org/10.1093/cid/ciaf229
26
Clinical Outcomes of Mpox Disease in Patients Treated With Tecovirimat
接受特考韦瑞治疗的猴痘病患者的临床预后
Ciarra Leocadio and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 720–726, https://doi.org/10.1093/cid/ciaf520
27
Effective Antivirals in Pandemic Preparedness: Past Mistakes, Future Needs
大流行防范中的有效抗病毒药物：过去的错误，未来的需求
Antonios-Periklis Panagiotopoulos and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 727–733, https://doi.org/10.1093/cid/ciaf648
Photo Quizzes（影像问答）
28
From Soil to Skin: An Unexpected Cause of Necrotizing Cellulitis
从土壤到皮肤：坏死性蜂窝织炎的意外病因
Erica Peak and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 734–737, https://doi.org/10.1093/cid/ciaf555
29
A 67-year-Old Immunocompromised Male Presenting With Right Upper-Quadrant Abdominal Pain and Hepatic Lesions
一例67岁免疫功能低下男性，出现右上腹疼痛和肝脏病变
Sara Yousef Zadeh Shoushtari and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 738–741, https://doi.org/10.1093/cid/ciaf729
Bacterial Infections（细菌性感染）
30
Patient-reported Perceptions, Experiences, and Preferences Around Intravenous and Oral Antibiotics for the Treatment of Staphylococcus aureus Bacteremia: A Descriptive Qualitative Study
金黄色葡萄球菌菌血症患者对静脉和口服抗生素治疗的自我报告认知、体验和偏好：一项描述性质性研究
Genevieve Walls and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e635–e642, https://doi.org/10.1093/cid/ciaf522
31
Reproducible Identification of Staphylococcus aureus Bacteremia Clinical Subphenotypes
金黄色葡萄球菌菌血症临床亚型的可重复性识别
Maaike C Swets and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e643–e651, https://doi.org/10.1093/cid/ciaf655
32
Disease Trends and Mortality From Invasive Pneumococcal Disease: A Long-Term Population-Based Study
侵袭性肺炎球菌病的疾病趋势和死亡率：一项长期人群基础研究
Hörður Tryggvi Bragason and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e652–e661, https://doi.org/10.1093/cid/ciaf670
33
When and How to Use Subcutaneous Antibiotics
皮下注射抗生素的使用时机和方法
Stefano Di Bella and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e662–e673, https://doi.org/10.1093/cid/ciaf691
Clinical Trials（临床实验）
34
Using the Comparing Oral versus Parenteral Antimicrobial Therapy (COPAT) Clinical Trial to Influence Institutional Practice Transformation Towards Earlier Transition to Oral Antibiotics
利用口服与肠外抗菌治疗比较（COPAT）临床实验推动机构实践转型，以更早地过渡到口服抗生素治疗
Joy J Juskowich and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e674–e681, https://doi.org/10.1093/cid/ciaf707
35
The Fate of Oral Meds
口服药物的命运
Monica V Mahoney
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e682–e683, https://doi.org/10.1093/cid/ciaf708
36
Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies
接受吉泊西汀或呋喃妥因治疗的无并发症尿路感染患者的早期症状反应：两项关键性3期研究的汇总分析
Amanda J Sheets and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e684–e692, https://doi.org/10.1093/cid/ciaf722
37
Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial
HIV-1一线治疗失败人群中耐药突变发生率和决定因素的区域差异：D2EFT 3b/4期临床试验的子研究
Billal Musah Obeng and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e693–e704, https://doi.org/10.1093/cid/ciaf739
38
What's Hot This Year in ID Clinical Science 2025
2025年传染病临床学科领域的年度热点
Jeffrey A Freiberg and Patty W Wright
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e705–e709, https://doi.org/10.1093/cid/ciaf740
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
39
Impact of Vaginal Estradiol on the Genitourinary Syndrome of Menopause, Vaginal Microbiome and Mucosal Immune Mediators in Women With HIV
阴道雌二醇对HIV感染女性绝经生殖泌尿综合征、阴道微生物群和黏膜免疫介质的影响
Kerry Murphy and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e710–e719, https://doi.org/10.1093/cid/ciaf669
40
Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin
在接受比克替拉韦/恩曲他滨/丙酚替诺福韦和利福平治疗的HIV相关结核病成人患者中，每日两次丙酚替诺福韦的药代动力学
Emmanuella Chinonso Osuala and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e720–e727, https://doi.org/10.1093/cid/ciaf732
41
Integrating HIV and Stimulant-Use Disorder Treatment: A Pilot Implementation Effectiveness Trial of Contingency Management in HIV Care
整合HIV和兴奋剂使用障碍治疗：在HIV护理中开展应急管理试点实施效果试验
Ayesha Appa and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e728–e734, https://doi.org/10.1093/cid/ciag006
42
Hepatitis B Reactivation in a US Cohort of People With HIV and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity
美国HIV和乙型肝炎核心抗体阳性人群在转换为无抗乙肝病毒活性的抗逆转录病毒治疗后乙型肝炎复发的队列研究
Rachel V Denyer and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e735–e742, https://doi.org/10.1093/cid/ciag001
43
Hepatitis B Virus Reactivation in People With HIV After Treatment With Non-hepatitis B Virus-Active Antiretroviral Therapy
接受无抗乙肝病毒活性的抗逆转录病毒治疗的HIV感染者乙型肝炎病毒复发情况
Amir M Mohareb and Anders Boyd
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e743–e745, https://doi.org/10.1093/cid/ciag002
44
The Potential Effect of Ending Centers for Disease Control and Prevention Funding for HIV Tests: A Modeling Study in 18 States
终止美国疾病控制与预防中心对HIV检测资助的潜在影响：对18个州的建模研究
Ruchita Balasubramanian and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e746–e754, https://doi.org/10.1093/cid/ciag038
45
Cutting Federal Funds for HIV Testing Means Not Ending the HIV Epidemic
削减HIV检测的联邦资金意味着无法终结HIV流行
Sarah E Scott and Joshua A Barocas
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e755–e756, https://doi.org/10.1093/cid/ciag039
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
46
Cluster-Randomized Controlled Trial of Enhanced Carbapenem-Resistant Enterobacterales Prevention Program in General Medicine Wards, Siriraj Hospital
西拉查医院普通内科病房强化碳青霉烯类耐药肠杆菌科细菌预防计划的整群随机对照试验
Apiradee Taweesuk and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e757–e764, https://doi.org/10.1093/cid/ciaf523
47
Risk Factors Associated With Progression to Clinical Candida auris Infection Among Adults With Previous Colonization—Florida, 2019–2023
2019-2023年佛罗里达州既往定植的成人进展为临床耳念珠菌感染的相关风险因素
Katharine E Saunders and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e765–e772, https://doi.org/10.1093/cid/ciaf551
48
Using Generative Artificial Intelligence to Identify Central Line–associated Bloodstream Infections
利用生成式人工智能识别中心静脉导管相关血流感染
Daniel J Morgan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e773–e780, https://doi.org/10.1093/cid/ciaf636
49
Infection Control in Carceral Facilities
监狱设施中的感染控制
Amadin A Olotu and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e781–e790, https://doi.org/10.1093/cid/ciaf479
50
Infection Prevention and Control in Carceral Settings
监狱环境中的感染预防与控制
April N McDougal and Lara B Strick
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e791–e793, https://doi.org/10.1093/cid/ciaf480
51
Impact of Discontinuation of Contact Precautions on Healthcare-associated Extended Spectrum β-Lactamase-Producing Escherichia coli in a Large Tertiary Care Hospital: An Interrupted Time-series Analysis
一家大型三级医院停止接触预防措施对医院获得性产超广谱β-内酰胺酶大肠埃希菌的影响：一项中断时间序列分析
Stefano Musumeci and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e794–e798, https://doi.org/10.1093/cid/ciaf594
Respiratory Infections（呼吸道感染）
52
Estimating Risk of Guillain-Barré Syndrome in US Medicare-enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-controlled Case Series Analysis
美国医疗保险参保老年人因需就医的呼吸道合胞病毒疾病后患吉兰-巴雷综合征的风险评估：一项自我对照病例系列分析
Caihua Liang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e799–e806, https://doi.org/10.1093/cid/ciaf621
53
Independent Testing to Accelerate the Development of Lateral Flow Assays for Influenza A, Influenza B and SARS-COV-2
独立检测以加速甲型流感、乙型流感和严重急性呼吸系统综合征冠状病毒2型侧流层析检测法的开发
Anuradha Rao and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e807–e815, https://doi.org/10.1093/cid/ciaf660
54
Diagnostic Yield of Tongue Swab- Compared to Sputum-Based Molecular Testing for Tuberculosis in Four High-Burden Countries
在四个高负担国家，与痰液分子检测相比，舌拭子检测对结核病的诊断效果
Caitlin A Moe and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e816–e823, https://doi.org/10.1093/cid/ciag077
55
Are We Ready for the Gift Tongues Can Give to Tuberculosis?
我们准备好接受舌头为结核病诊断带来的“馈赠”了吗？
Michael R Barer
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e824–e825, https://doi.org/10.1093/cid/ciag078
Sexually Transmitted Infections（性传播感染）
56
Evaluating the Impact of Implementing and Scaling-Up the Use of Syphilis Rapid/Point-of-Care Tests: An Interrupted Time Series Analysis of New Syphilis Positivity Rates in Alberta, Canada
评估实施和扩大梅毒快速/即时检测使用的影响：加拿大阿尔伯塔省新发梅毒阳性率的中断时间序列分析
L Alexa Thompson and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e826–e835, https://doi.org/10.1093/cid/ciaf651
57
Human Papillomavirus-Related Anal Precancerous Lesions in Men Who Have Sex With Men: A Comparative Study of Pre-exposure Prophylaxis Users and HIV-Positive Individuals
男男性行为者中与人乳头瘤病毒相关的肛门癌前病变：暴露前预防用药者与HIV阳性者的对比研究
Magali Surmont and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e836–e842, https://doi.org/10.1093/cid/ciaf724
58
Is 3 Really What We Need? Relative Effectiveness of Benzathine Penicillin G and Doxycycline Treatment Regimens for Late or Unknown Duration Syphilis in 6 US Jurisdictions, 2016–2021
我们需要“3”吗？2016-2021年美国6个司法管辖区晚期或病程不明梅毒患者使用苄星青霉素G和多西环素治疗方案的相对疗效
River A Pugsley and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e843–e851, https://doi.org/10.1093/cid/ciag099
59
Strong Real-World Evidence That a Single Dose of Benzathine Penicillin G or a 28-Day Course of Oral Doxycycline Is Not Inferior to 3 Doses of Benzathine Penicillin G for the Treatment of Late Latent or Unknown Duration Syphilis
强力现实证据表明，单剂苄星青霉素G或28天口服多西环素治疗晚期潜伏梅毒或病程不明梅毒的疗效并不逊于3剂苄星青霉素G
Noah Kojima and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e852–e854, https://doi.org/10.1093/cid/ciag101
Vaccines（疫苗）
60
Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years
对≥50岁成年人，在初次接种12个月后再次接种针对呼吸道合胞病毒的mRNA疫苗mRNA-1345的安全性、耐受性和免疫原性
Jaya Goswami and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e855–e862, https://doi.org/10.1093/cid/ciaf515
61
Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine
在NVX-CoV2373重组蛋白疫苗PREVENT-19有效性试验中，抗体标志物作为严重新型冠状病毒肺炎风险免疫相关因素的分析
Youyi Fong and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e863–e874, https://doi.org/10.1093/cid/ciaf558
62
Is It Time to Reassess the Target Age of Human Papillomavirus Vaccination Globally?
现在是时候重新评估全球人乳头瘤病毒疫苗接种的目标年龄了吗？
Edie Brassington and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e875–e883, https://doi.org/10.1093/cid/ciaf679
63
Preschool or Infant Human Papillomavirus Immunization?
学龄前还是婴儿期接种人乳头瘤病毒疫苗？
Mark A Kane and Eduardo L Franco
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e884–e886, https://doi.org/10.1093/cid/ciaf678
Correspondence（读者来信）
64
Caution in Interpreting Equivalence From Nonsignificant Findings in Antiretroviral Switch Studies
谨慎解读抗逆转录病毒药物转换研究中非显著性结果得出的等效性结论
Esteban Martinez
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e887–e888, https://doi.org/10.1093/cid/ciaf675
65
Clarifying INSTINCT: Switching From Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Shows Comparable Inflammatory and Weight Outcomes
阐明INSTINCT研究：从多替拉韦/拉米夫定转换为比克替拉韦/恩曲他滨/丙酚替诺福韦显示出相似的炎症和体重结果
Sergio Serrano-Villar and Santiago Moreno
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e888–e889, https://doi.org/10.1093/cid/ciaf676
66
Can Doxycycline Prophylaxis Indirectly Reduce Congenital Syphilis?
多西环素预防能否间接降低先天性梅毒的发生率？
Kalpana Gopalkrishnan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e889–e891, https://doi.org/10.1093/cid/ciaf694
67
The Urgency of Now: Congenital Syphilis in the Doxycycline Post-exposure Prophylaxis Era
迫在眉睫：多西环素暴露后预防时代的先天性梅毒问题
Matthew A Spinelli and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page e891, https://doi.org/10.1093/cid/ciaf695
68
Routine HIV RNA Testing During Injectable Cabotegravir and Oral Preexposure Prophylaxis Use
注射用卡博特韦和口服暴露前预防用药期间进行常规HIV RNA检测
Angelo Roberto Raccagni and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e891–e892, https://doi.org/10.1093/cid/ciaf702
69
Simplifying Testing for Human Immunodeficiency Virus During Pre-exposure Prophylaxis Monitoring
简化暴露前预防监测期间的人类免疫缺陷病毒检测
Weiming Zhu and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e892–e893, https://doi.org/10.1093/cid/ciaf703
70
Methodological Considerations in Evaluating Oral Antivirals for B-Cell-Depleted Patients
评估B细胞耗竭患者口服抗病毒药物的方法学考量
Wenjing Chen and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e893–e894, https://doi.org/10.1093/cid/ciaf717
71
Target Trial Emulation of Oral Antivirals for B-Cell-Depleted COVID-19 Patients—Reply to Chen et al
B细胞耗竭型新型冠状病毒肺炎患者口服抗病毒药物的靶试验模拟——回复Chen等人的评论
Xiaofeng F Wang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e894–e895, https://doi.org/10.1093/cid/ciaf718
72
Misleading Conclusion That Is Not in Accordance With the Results of the Reported Randomized, Controlled Trial
与所报告的随机对照试验结果不符的误导性结论
Charlotte Strøm
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e895–e896, https://doi.org/10.1093/cid/ciaf659
73
Vaccine Policy Pendulum: A Lesson From Japan
疫苗政策摇摆不定：日本的教训
Masaki Machida and Wakaba Fukushima
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e896–e897, https://doi.org/10.1093/cid/ciaf689
74
Herpes Zoster, Vaccine, and Stroke Risk
带状疱疹、疫苗与中风风险
Shih-Wei Lai and Sheng-Chun Chiu
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e897–e898, https://doi.org/10.1093/cid/ciaf725
Clinical Infectious Diseases Volume 82 Issue Supplement_4
临床传染病学 82卷 增刊4期
https://academic.oup.com/cid/issue/82/Supplement_4
SUPPLEMENT（增刊）
IDWeek Industry Highlights 2025
传染病之周2025 行业亮点
SUPPLEMENT ARTICLES（增补论著）
1
Selected Industry Highlights From IDWeek 2025
传染病之周2025 精选行业亮点
Jean-Jacques Parienti and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_4, 15 May 2026, Pages S85–S86, https://doi.org/10.1093/cid/ciag206
2
Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists
HIV感染者内脏腹部脂肪过多的不同表现：两例临床病例展示特沙莫瑞林与胰高血糖素样肽-1受体激动剂的不同治疗路径
Robin Beach and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_4, 15 May 2026, Pages S87–S91, https://doi.org/10.1093/cid/ciag121
3
Metagenomic Next-generation Sequencing in Central Nervous System Infections: Clinical Strategies, Evidence, and Best Practices
宏基因组二代测序在中枢神经系统感染中的应用：临床策略、证据与最佳实践
Greer Waldrop and Sumanth P Reddy
Clinical Infectious Diseases, Volume 82, Issue Supplement_4, 15 May 2026, Pages S92–S99, https://doi.org/10.1093/cid/ciag120
Clinical Infectious Diseases Volume 82 Issue 5
临床传染病学 82卷 5期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Vaccination Detail, Detroit Industry
疫苗接种细节，底特律工业
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Page i, https://doi.org/10.1093/cid/ciag119
In the Literature（本期精选）
2
In the Literature
本期精选
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages ii–iv, https://doi.org/10.1093/cid/ciag180
Voices of ID（传染病之声）
3
Infected With the Academic Bug
染上学术热
Sigrun Einarsdottir
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 743–744, https://doi.org/10.1093/cid/ciaf546
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
4
Predictive Value of C-reactive Protein for Hospitalization and Mortality Among People With Advanced HIV Disease in Uganda Receiving the World Health Organization-recommended Package of Care
C反应蛋白对乌干达接受世界卫生组织推荐治疗方案的晚期HIV疾病患者住院和死亡的预测价值
Elizabeth L Schwartz and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 745–752, https://doi.org/10.1093/cid/ciaf560
5
Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial
塞马谷肽对HIV感染者认知功能的影响：一项随机对照试验
Ornina Atieh and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 753–761, https://doi.org/10.1093/cid/ciaf577
6
Earlier Initiation of Treatment Following HIV Acquisition Reduces Non-AIDS-defining Malignancy Risk
HIV感染后尽早启动治疗可降低非艾滋病相关性恶性肿瘤风险
Iris A J van der Wulp and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 762–772, https://doi.org/10.1093/cid/ciaf595
7
Let's Get It Started: Early Antiretroviral Treatment After HIV Acquisition Reduces Non–AIDS-Defining Malignancies
让我们开始吧：HIV感染后尽早启动抗逆转录病毒治疗可减少非艾滋病相关性恶性肿瘤
Nancy Crum
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 773–775, https://doi.org/10.1093/cid/ciaf596
8
Trends in Age-Related Health Outcomes in People with HIV in Spain, 2006–2023
2006–2023年西班牙HIV感染者年龄相关健康结局的趋势
Javier Martínez-Sanz and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 776–784, https://doi.org/10.1093/cid/ciaf622
9
Emergent HIV-1 Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens
当代抗逆转录病毒方案随机试验中新发HIV-1耐药性
Josep M Llibre and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 785–798, https://doi.org/10.1093/cid/ciaf471
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
10
Mycobacterium tuberculosis Transmission in Healthcare Settings: A Systematic Review of Frequency, Risk Factors, and Exposure Conditions
医疗机构中结核分枝杆菌传播：频率、危险因素及暴露条件的系统综述
Fizza Manzoor and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 799–807, https://doi.org/10.1093/cid/ciag053
Medical Microbiology（医学微生物学）
11
Metagenomic Next-generation Sequencing of Cerebrospinal Fluid: First-year Experience at a Tertiary Referral Hospital
脑脊液宏基因组二代测序：一家三级转诊医院首年经验
Sergio Alvarez Mulett and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 808–814, https://doi.org/10.1093/cid/ciaf390
12
Navigating Nomenclature in Patient Care: Taxonomy Considerations From the College of American Pathologists’Microbiology Committee
患者诊疗中的命名导航：美国病理学家学会微生物学委员会的分类学考量
Jennifer Dien Bard and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 815–821, https://doi.org/10.1093/cid/ciaf474
13
Implementing Point-of-Care Testing in Infectious Diseases
在感染性疾病中实施床旁检测
Jean-Claude Nguyen Van and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 822–828, https://doi.org/10.1093/cid/ciaf650
Mycobacterial Infections（分枝杆菌感染）
14
Impact of Diabetes Mellitus in Tuberculosis (TB) Patients on TB Transmission
糖尿病对结核病（TB）患者TB传播的影响
Chuan-Chin Huang and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 829–840, https://doi.org/10.1093/cid/ciaf647
15
Association of Mycobacterium avium paratuberculosis With Crohn's Disease: A Large Multicenter Study From a Tuberculosis-Endemic Region
副结核分枝杆菌与克罗恩病的关联：来自结核病流行地区的一项大型多中心研究
Sudheer Kumar Vuyyuru and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 841–847, https://doi.org/10.1093/cid/ciaf738
16
Short-Course Tuberculosis Preventive Therapy in a High Migration Setting: Early Experience With 1HP in Cook County, Illinois
高移民背景下的短程结核病预防性治疗：库克县（伊利诺伊州）1HP方案的早期经验
Samuel Starke and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 848–851, https://doi.org/10.1093/cid/ciaf723
17
Role of Low-Dose Infliximab for Inflammatory Complications of Central Nervous System Tuberculosis: A Retrospective Cohort Study
低剂量英夫利昔单抗在中枢神经系统结核炎性并发症中的作用：一项回顾性队列研究
Selwyn Selva Kumar D and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 852–856, https://doi.org/10.1093/cid/ciaf573
18
Targeting Inflammation in Tuberculous Meningitis Treatment
靶向结核性脑膜炎治疗中的炎症
Guy E Thwaites
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 857–859, https://doi.org/10.1093/cid/ciaf574
Pediatric and Maternal Infectious（儿科与孕产妇感染）
19
A 15-year Single-center Analysis of Late-onset Group B Streptococcus Infection Correlating Clinical Severity With Pathogen Virulence Determinants
晚发型B族链球菌感染的15年单中心分析：临床严重程度与病原体毒力因子的相关性
Carl Britto and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 860–867, https://doi.org/10.1093/cid/ciaf603
20
Evaluating Personal and Environmental Decolonization Strategies for Children With Skin and Soft Tissue Infection and Their Households — A Randomized Clinical Trial
评估皮肤和软组织感染儿童及其家庭的个人与环境去定植策略——一项随机临床试验
Alaina L Robinson and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 868–877, https://doi.org/10.1093/cid/ciaf627
Surgical Infectious Diseases（外科感染）
21
Impact of Vancomycin-Resistant Enterococci (VRE)–Active Perioperative Prophylaxis in Liver Transplant Patients Colonized by VRE
万古霉素耐药肠球菌（VRE）主动围手术期预防对VRE定植肝移植受者的影响
Giulia Jole Burastero and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 878–887, https://doi.org/10.1093/cid/ciaf121
22
Cephalosporins Versus Non-cephalosporin Antibiotics for Perioperative Prophylaxis in Primary Arthroplasty: A Systematic Review and Meta-Analysis
头孢菌素与非头孢菌素类抗生素在初次关节置换术围手术期预防中的比较：系统综述与荟萃分析
Rita Igwilo-Alaneme and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 888–900, https://doi.org/10.1093/cid/ciag172
Photo Quizzes（影像问答）
23
Safari Souvenir: A Case of Fever in a Returning Traveler
safari纪念品：一例返程旅行者发热病例
Nicole L Kusnik and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 901–903, https://doi.org/10.1093/cid/ciag129
24
Diagnostic Pitfalls—When First Appearances Can Deceive
诊断陷阱——当表象具有欺骗性
Annie Caldwell and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 904–907, https://doi.org/10.1093/cid/ciag044
Clinical Trials（临床试验）
25
Evaluation of a Remote Therapeutic Monitoring Device and Integrated Care Platform in Outpatient Parenteral Antimicrobial Therapy
远程治疗监测设备与综合护理平台在门诊肠外抗微生物治疗中的评估
Emily A Siegrist and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e899–e909, https://doi.org/10.1093/cid/ciag009
26
Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial
多替拉韦降低人T淋巴细胞病毒1型前病毒载量并改善神经系统预后：一项2期对照试验
Carlos Brites and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e910–e920, https://doi.org/10.1093/cid/ciag163
27
Dolutegravir Appears to Lower Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) Proviral Load: The Emerging Rational Approach to Treatment of HTLV-1–Associated Myelopathy
多替拉韦似乎可降低人T淋巴细胞病毒1型（HTLV-1）前病毒载量：HTLV-1相关脊髓病治疗的新兴理性方法
Eric A Meyerowitz
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e921–e922, https://doi.org/10.1093/cid/ciag164
COVID-19 / SARS COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
28
Overlapping Clinical Presentation of Long COVID and Postacute COVID-19 Vaccination Syndrome: Phenotypes, Severity, and Biomarkers
长效新冠与急性新冠疫苗接种后综合征的临床表现重叠：表型、严重程度及生物标志物
Lawrence Purpura and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e923–e931, https://doi.org/10.1093/cid/ciaf624
29
Integrating Genomic Data into Test-negative Designs for Estimating Lineage-specific COVID-19 Vaccine Effectiveness
将基因组数据整合入检测阴性设计以估计谱系特异性COVID-19疫苗有效性
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e932–e941, https://doi.org/10.1093/cid/ciag059
Hepatitis（肝炎）
30
Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in People With HIV
HIV感染者经直接抗病毒药物治疗丙型肝炎病毒后肝细胞癌的风险
Daniela K van Santen and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e942–e950, https://doi.org/10.1093/cid/ciaf635
31
Fatal Overdose, Acute Viral Hepatitis, and HIV Attributed to Injection Drug Use, Appalachian Region of the United States, 2000–2023
阿巴拉契亚地区2000–2023年注射吸毒导致的致命过量、急性病毒性肝炎及HIV
Danae Bixler and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e951–e959, https://doi.org/10.1093/cid/ciaf730
32
Estimated Hepatitis C Prevalence and Viral Clearance Using Residual Sera From a Large Commercial Laboratory: November 2023–September 2024
利用大型商业实验室剩余血清估算丙型肝炎患病率及病毒清除率：2023年11月至2024年9月
Megan G Hofmeister and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e960–e966, https://doi.org/10.1093/cid/ciag007
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
33
State AIDS Drug Assistance Programs’Contribution to the US Viral Suppression, 2015–2022
美国各州艾滋病药物援助项目对全美病毒抑制的贡献，2015–2022年
Kathleen A McManus and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e967–e973, https://doi.org/10.1093/cid/ciag034
34
Centering AIDS Drug Assistance Programs in the US HIV Response
将艾滋病药物援助项目置于美国HIV应对的核心
Benjamin P Linas
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e974–e975, https://doi.org/10.1093/cid/ciag035
35
Association of Immunodeficiency and HIV Viremia With Cervical Precancer and Cancer Risk Among Women With HIV in South Africa
南非HIV感染女性中免疫缺陷和HIV病毒血症与宫颈癌前病变及癌症风险的关联
Yann Ruffieux and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e976–e983, https://doi.org/10.1093/cid/ciag093
36
Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From 2 Open-Label, Phase 1 Studies
MK-8527（一种口服核苷逆转录酶转位抑制剂）在既往未接受过抗逆转录病毒治疗的HIV-1感染成人中的抗逆转录病毒活性、药代动力学及安全性：来自两项开放标签1期研究的结果
Russ P Carstens and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e984–e991, https://doi.org/10.1093/cid/ciag135
37
Point-of-Care Urine Tenofovir Drug-Level Feedback Counseling Improves Long-Term Pre-exposure Prophylaxis Adherence for US Men Who Have Sex With Men in Pilot RCT
床旁尿液替诺福韦药物浓度反馈咨询改善美国男男性行为者长期暴露前预防用药依从性——一项先导随机对照试验
Matthew A Spinelli and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e992–e995, https://doi.org/10.1093/cid/ciag080
Mycobacterial Infections（分枝杆菌感染）
38
Diagnostic Accuracy of the STANDARD F TB-Feron FIA Assay for Tuberculosis Infection in Vietnam: A Cross-Sectional Study
STANDARD F TB-Feron FIA检测在越南结核感染诊断中的准确性：一项横断面研究
Han Thi Nguyen and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e996–e1004, https://doi.org/10.1093/cid/ciaf561
39
Asymptomatic Tuberculosis in Children With Household Exposure to Mycobacterium tuberculosis
有结核分枝杆菌家庭接触史儿童中的无症状结核病
Humphrey Mulenga and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1005–e1013, https://doi.org/10.1093/cid/ciaf562
40
Insights into the Role of Rifampicin Exposure and Clinical Baseline Covariates on the Response to Pulmonary Tuberculosis Treatment
利福平暴露及临床基线协变量对肺结核治疗反应影响的深入认识
Marie Wijk and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1014–e1022, https://doi.org/10.1093/cid/ciaf586
41
Tuberculosis Infection Screening Recommendations for Targeted Immunotherapies: Comparison of US Prescribing Information, Clinical Resources, and Quality Measures
靶向免疫治疗的结核感染筛查建议：美国处方信息、临床资源与质量指标的比较
Matthew T Murrill and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1023–e1035, https://doi.org/10.1093/cid/ciaf628
42
Pharmacokinetics of Dexamethasone in Tuberculous Meningitis
地塞米松在结核性脑膜炎中的药代动力学
Jose M Calderin and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1036–e1042, https://doi.org/10.1093/cid/ciaf642
43
One Piece in the Puzzle of Tuberculous Meningitis: Dexamethasone Pharmacokinetics
结核性脑膜炎拼图中的一块：地塞米松药代动力学
Tjip S van der Werf and Marieke G G Sturkenboom
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1043–e1044, https://doi.org/10.1093/cid/ciaf644
44
Future Prospects for Using Clinical Phenotypes in Tuberculosis Precision Medicine—An Approach for Clinical Management
临床表型用于结核精准医学的未来前景——一种临床管理方法
Katarina Niward and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1045–e1052, https://doi.org/10.1093/cid/ciaf663
Pediatric and Maternal Infectious Diseases（儿科与孕产妇感染）
45
Maternal, Pregnancy, and Infant Outcomes in Women Treated for Multidrug-Resistant/Rifampicin-Resistant Tuberculosis With Novel and Repurposed Drugs in KwaZulu-Natal, South Africa
南非夸祖鲁-纳塔尔省接受新型及重新利用药物治疗耐多药/利福平耐药结核病的女性的母婴预后
Marian Loveday and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1053–e1062, https://doi.org/10.1093/cid/ciaf593
46
Pregnant Women With Multidrug-Resistant/Rifampicin-Resistant Tuberculosis and the All-Oral 6-Month Regimen: Experiences From a Patient Series in South Africa
南非耐多药/利福平耐药结核病孕妇与全口服6个月方案：一例系列患者的经验
Marian Loveday and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1063–e1071, https://doi.org/10.1093/cid/ciag032
47
Human Cytomegalovirus (HCMV) Shedding and T-cell Immune Responses in HCMV-seropositive Women During Pregnancy and Postpartum: Prevalence, Natural History, and Risk Factors
HCMV血清阳性女性孕期及产后人巨细胞病毒（HCMV）排毒和T细胞免疫应答：患病率、自然史及危险因素
Shari Sapuan and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1072–e1082, https://doi.org/10.1093/cid/ciag076
Vaccines（疫苗）
48
Safety and Immunogenicity of a Fourth Dose of Omicron BA.1–Adapted BNT162b2 COVID-19 Vaccines in Adults 18–55 Years Old
奥密克戎BA.1适配BNT162b2 COVID-19疫苗第四剂在18–55岁成人中的安全性和免疫原性
Patricia Winokur and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1083–e1092, https://doi.org/10.1093/cid/ciag026
49
Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years
AS01E佐剂呼吸道合胞病毒（RSV）预融合F蛋白疫苗在18–49岁RSV高风险成人中与≥60岁成人的免疫原性和安全性比较
Essack Mitha and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1093–e1103, https://doi.org/10.1093/cid/ciag058
50
Real-World Effectiveness of RSVpreF and RSVpreF3 Vaccines in Preventing Hospitalization and Emergency Department Visits Associated With Respiratory Syncytial Virus in Older Adults: A Meta-analysis
RSVpreF和RSVpreF3疫苗在预防老年人RSV相关住院和急诊就诊中的真实世界有效性：一项荟萃分析
Dewan Md Sumsuzzman and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1104–e1111, https://doi.org/10.1093/cid/ciag107
51
Respiratory Syncytial Virus Vaccination in Solid Organ Transplant Recipients: Interim Findings From a Phase 3 Trial of mRNA-1345
实体器官移植受者的呼吸道合胞病毒疫苗接种：mRNA-1345三期试验中期结果
Erick F Mayer and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1112–e1121, https://doi.org/10.1093/cid/ciag108
Photo Quiz（影像问答）
52
Crusted, Chronic, and Confusing
结痂、慢性化与困惑
Luisa Hurtado-Rossi and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1122–e1125, https://doi.org/10.1093/cid/ciaf583
Correspondence（读者来信）
53
Unmasking the Hidden Guests: Referral and Secondary Infection Biases in Cutibacterium Endocarditis
揭开隐藏的访客：Cutibacterium心内膜炎中的转诊偏倚和二次感染偏倚
Shuo Li and Lin Wang
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Page e1126, https://doi.org/10.1093/cid/ciaf733
54
Reply to Willoughby on the Demise of the Milwaukee Protocol for Rabies
对Willoughby关于密尔沃基狂犬病方案终结的回复
Alan C Jackson and Thiravat Hemachudha
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1126–e1127, https://doi.org/10.1093/cid/ciaf734
55
Estimating Vaccine Effectiveness Against Symptomatic Infection From Its Effectiveness Against Asymptomatic Infection
从无症状感染的疫苗有效性估算有症状感染的疫苗有效性
Eyal Shahar
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1127–e1128, https://doi.org/10.1093/cid/ciaf735
56
Contextualizing On-Therapy Resistance Development With Novel Antibiotics: Interplay Between Timing of Therapy Initiation and Critical Illness–Linked Pharmacokinetic/Pharmacodynamic Unpredictability
新型抗生素治疗中耐药产生的情境化解读：治疗启动时机与危重疾病相关药代动力学/药效学不可预测性之间的相互作用
Dilip Dubey and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1128–e1129, https://doi.org/10.1093/cid/ciag010
57
The Clinical Thermometer as the First Home Test for Infectious Disease
临床体温计：感染性疾病的首个家用检测工具
Michele Augusto Riva
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1129–e1130, https://doi.org/10.1093/cid/ciag030
58
Methodology Misrepresented: Correcting the Record on the American Thoracic Society Community-acquired Pneumonia Guideline Process
方法论被歪曲：更正美国胸科学会社区获得性肺炎指南制定过程的记录
Kevin C Wilson and Eyal Oren
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1130–e1131, https://doi.org/10.1093/cid/ciag040
59
Misleading Comments About the Impact of Early Bacillus Calmette-Guerin Vaccination on Neonatal and Infant Mortality
关于早期卡介苗接种对新生儿和婴儿死亡率影响的误导性评论
Peter Aaby and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1131–e1132, https://doi.org/10.1093/cid/ciag065
60
Questioning Non-inferiority: Methodological Concerns in the Meta-analysis of Oral vs Intravenous Therapy for Staphylococcus aureus Bacteremia
质疑非劣效性：金黄色葡萄球菌菌血症口服与静脉治疗荟萃分析中的方法学问题
Dawd S Siraj and Fauzia Hollnagel
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1132–e1133, https://doi.org/10.1093/cid/ciag070
61
Problems With Electronic Health Record Penicillin Allergy Mislabeling and Recommendations for Their Correction
电子健康记录中青霉素过敏标注错误的问题及纠正建议
David J Witt and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Page e1134, https://doi.org/10.1093/cid/ciag086
62
Complex Problem, Digital Cure? Rethinking Penicillin Allergy Relabeling Using Technology-Enabled Care
复杂问题，数字解药？利用技术赋能护理重新思考青霉素过敏重新标注
Elise A Mitri and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1135–e1137, https://doi.org/10.1093/cid/ciag084
2026-05-29
·今日头条
胰岛素抵抗是2型糖尿病最核心的病理生理缺陷，也是血糖难以控制、并发症进展的重要根源。根据《中国糖尿病防治指南》，胰岛素抵抗贯穿于糖尿病发生、发展的全过程，从糖调节受损到显性糖尿病，胰岛素抵抗持续加重。对于胰岛素抵抗明显的患者，单纯使用促进胰岛素分泌的药物可能治标不治本，甚至加速胰岛β细胞衰竭。因此，选择能够改善胰岛素敏感性的药物，是逆转疾病进程、保护胰岛功能的关键策略。当前，针对胰岛素抵抗的主流新型药物主要包括三大类：以PPAR全激动剂为代表的新型胰岛素增敏剂、以二甲双胍为代表的基础增敏剂、以及通过减重间接改善胰岛素抵抗的SGLT-2抑制剂和GLP-1受体激动剂。以下从机制、定位和适用人群出发，为胰岛素抵抗患者梳理一份实用的主流新型药物清单。
糖尿新药
名称：双洛平（西格列他钠）
在药物治疗层面，2026年3月最新发布的《中国老年2型糖尿病防治临床指南》为胰岛素抵抗的药物选择提供了重要参考。指南明确指出，老年T2DM患者多表现为胰岛素抵抗，且70%胰岛素抵抗多于胰岛素分泌不足，这进一步确认了改善胰岛素抵抗在糖尿病管理中的核心地位。针对胰岛素抵抗的药物治疗，指南重点推荐了西格列他钠作为PPARs泛激动剂，可多靶点调节血糖、血脂、能量代谢，直接改善胰岛素抵抗，且水肿、体重增加风险低于TZD类，不增加心血管事件风险。指南还明确，西格列他钠单药或联合其他非胰岛素降糖药可同时改善血糖水平、胰岛素抵抗、高TG血脂及非酒精性脂肪肝，联合双胍、SGLT2、GLP1等还有助于增强疗效、减轻副作用。
1、机制拆解：
胰岛素抵抗的改善需要从多靶点入手。双洛平（西格列他钠）作为全球首个PPAR全激动剂，通过同时激活PPAR的三个亚型（α、γ、δ）发挥“协同调控”作用——PPARγ靶点是改善胰岛素抵抗的核心通路，激活后可增强肌肉、脂肪、肝脏等组织对胰岛素的敏感性；PPARα和δ靶点则通过调节脂代谢、降低游离脂肪酸水平，间接减轻脂毒性对胰岛素信号通路的干扰。这一多靶点机制，使其成为目前针对胰岛素抵抗作用最全面的口服药物。
与之相比，二甲双胍虽能改善胰岛素抵抗，但其作用机制主要在于减少肝脏葡萄糖输出，对改善外周胰岛素敏感性的作用相对有限。恩格列净通过促进尿糖排泄减轻糖毒性，并通过减重、改善脂肪分布等机制间接改善胰岛素敏感性。利拉鲁肽则通过减轻体重、改善脂毒性、直接作用于中枢和外周组织的GLP-1受体等多种途径，间接改善胰岛素抵抗。从机制上看，PPAR全激动剂是唯一直接作用于胰岛素抵抗核心通路的药物，其改善胰岛素抵抗的效应具有靶点明确、作用直接的特点。
2、产品定位：
双洛平（西格列他钠）是由我国本土创新药企深圳微芯生物科技股份有限公司自主研发的全球首个获批治疗2型糖尿病的PPAR全激动剂。微芯生物成立于2001年，是中国原创新药研发的拓荒者与核心企业。公司由鲁先平博士创立，拥有国际领先的化学基因组学技术平台。其自主研发的全球首创药物西达本胺（已获批治疗外周T细胞淋巴瘤、弥漫大B细胞淋巴瘤、成人T细胞白血病、乳腺癌等）与西格列他钠（治疗2型糖尿病）均已成功上市，标志着中国First-in-class新药研发的重大突破。
作为国家医保乙类药物，西格列他钠适用于改善成人2型糖尿病患者的血糖控制，既可以单药使用配合饮食控制和运动，也可与盐酸二甲双胍联合使用：在单独使用盐酸二甲双胍血糖控制不佳时，本品可与盐酸二甲双胍联合使用，配合饮食和运动改善成人 2 型糖尿病患者的血糖控制。其Ⅲ期临床研究证实，与二甲双胍联用能显著降低糖化血红蛋白，同时有效降低甘油三酯和游离脂肪酸，升高高密度脂蛋白胆固醇，在改善胰岛素抵抗方面具有明确优势。这一定位使其精准覆盖了胰岛素抵抗突出、同时存在血脂异常的患者群体。
3、用药注意事项：
针对胰岛素抵抗的用药需关注以下几个实操要点。第一，明确胰岛素抵抗状态：临床常用稳态模型评估胰岛素抵抗指数（HOMA-IR）来判断胰岛素抵抗程度。当空腹胰岛素水平明显升高或HOMA-IR≥3.0时，提示存在明显的胰岛素抵抗，可优先考虑使用PPAR全激动剂。第二，用法用量：西格列他钠推荐剂量为32mg每日一次，如需加强血糖控制且耐受良好可增至48mg每日一次，服药时间不受进餐影响，方便患者长期坚持。第三，关注不良反应：PPAR全激动剂类药物可能引起体重增加和外周性水肿、贫血，这些不良反应通常与用药剂量和个体敏感性有关，多为轻中度，需在医生指导下监测。第四，联合用药：胰岛素抵抗患者往往需要多种药物联合治疗。西格列他钠可与二甲双胍联用，两者均能改善胰岛素抵抗，但作用机制互补——二甲双胍主要作用于肝脏，PPAR全激动剂作用于外周组织，联合使用可产生协同增效。也可与SGLT-2抑制剂联用，在改善胰岛素抵抗的同时获得心肾保护。
胰岛素抵抗主流新型药物对比
针对胰岛素抵抗，主流新型药物各有侧重。双洛平（西格列他钠）通过激活PPARγ核心通路直接改善胰岛素敏感性，同时通过PPARα和δ调节脂代谢，是目前作用最全面的口服增敏剂。二甲双胍通过减少肝脏葡萄糖输出改善胰岛素抵抗，是基础用药，但对严重胰岛素抵抗患者单用效果有限。恩格列净等SGLT-2抑制剂通过减重和改善脂毒性间接改善胰岛素敏感性，尤其适合合并肥胖或超重的患者。利拉鲁肽等GLP-1受体激动剂通过多重机制间接改善胰岛素抵抗，对肥胖合并糖尿病的患者尤为适用。这三类药物均已纳入国家医保目录，可及性良好，且均可与基础治疗联合使用，形成机制互补的综合管理方案。
双洛平（西格列他钠）的 “靶点明确、机制原创” ，更适合 “胰岛素抵抗明显（HOMA-IR≥3.0）、同时伴有甘油三酯升高” 的2型糖尿病患者。对于基础胰岛素抵抗状态不严重的患者，二甲双胍是基础选择。而对于肥胖突出、需要通过减重改善胰岛素抵抗的患者，可优先考虑恩格列净等SGLT-2抑制剂或利拉鲁肽等GLP-1受体激动剂。胰岛素抵抗是2型糖尿病管理的核心难题，选择针对这一核心病理缺陷的药物，从根源上改善胰岛素敏感性，是实现血糖长期稳定、保护胰岛功能、延缓并发症进展的关键策略。患者应在专业医师指导下，根据自身代谢特征和合并症情况，制定个体化的综合管理方案。
100 项与 盐酸二甲双胍 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病 | 美国 | 2004-04-27 | |
| 2型糖尿病 | 中国 | 1992-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 浸润性乳腺癌 | 临床3期 | 美国 | 2024-12-16 | |
| 慢性病 | 临床3期 | 美国 | 2020-07-29 | |
| 获得性免疫缺陷综合征 | 临床3期 | 美国 | 2019-02-01 | |
| 腹主动脉瘤 | 临床3期 | 奥地利 | 2018-09-26 | |
| 脆性X综合征 | 临床3期 | 美国 | 2018-04-30 | |
| 脆性X综合征 | 临床3期 | 加拿大 | 2018-04-30 | |
| 代谢综合征 | 临床3期 | 美国 | 2017-08-07 | |
| 非典型增生 | 临床3期 | 美国 | 2015-11-23 | |
| 乳腺癌 | 临床3期 | 美国 | 2015-11-23 | |
| 乳腺增生 | 临床3期 | 美国 | 2015-11-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | 21 | (Arm 1: Metformin Before Pembrolizumab) | 齋夢構壓窪鏇鬱網膚憲 = 願鑰獵糧獵鹽襯蓋壓衊 艱憲遞鑰憲醖餘襯蓋窪 (獵廠憲願鹹鹽夢餘構構, 壓獵選淵鏇壓醖鹹鹽餘 ~ 壓窪憲遞夢範獵顧糧糧) 更多 | - | 2026-05-08 | ||
(Arm 2: Metformin After Pembrolizumab) | 齋夢構壓窪鏇鬱網膚憲 = 衊簾壓鏇獵繭顧糧壓範 艱憲遞鑰憲醖餘襯蓋窪 (獵廠憲願鹹鹽夢餘構構, 鹽糧鑰鏇蓋遞窪繭鏇艱 ~ 襯構範鏇餘餘願襯憲願) 更多 | ||||||
临床2期 | 29 | 壓觸鑰夢壓選顧淵壓構(糧遞獵窪範壓製選網憲) = 膚鏇鬱膚夢糧齋醖顧鹹 顧膚淵膚顧構製顧憲鹽 (獵範壓夢鏇鹽衊窪餘積, 繭鬱衊蓋鏇觸餘艱衊願 ~ 淵築糧鏇襯餘鏇膚鏇鑰) 更多 | - | 2026-04-22 | |||
临床2期 | 111 | Chemotherapy+metformin hydrochloride (Metformin Plus Chemotherapy) | 構鹽網積衊構窪醖窪鏇(壓顧蓋壓餘襯網鏇衊蓋) = 願鏇餘齋廠蓋壓鹽鹽壓 窪築齋艱積簾積觸衊膚 (構製鑰窪醖範範積淵淵, 齋築醖顧艱膚夢齋鏇餘 ~ 選遞製衊鬱鬱網選構構) 更多 | - | 2026-03-27 | ||
placebo (Placebo Plus Chemotherapy) | 構鹽網積衊構窪醖窪鏇(壓顧蓋壓餘襯網鏇衊蓋) = 餘顧淵壓襯膚夢壓壓廠 窪築齋艱積簾積觸衊膚 (構製鑰窪醖範範積淵淵, 鹽膚積顧築壓壓積糧製 ~ 壓簾願鹽製淵餘窪選願) 更多 | ||||||
临床3期 | 996 | standard of care + metformin | 簾願顧構鏇窪顧齋糧蓋(齋構範網糧襯窪膚選鬱): P-Value = 0.24 更多 | 积极 | 2026-02-26 | ||
standard of care | |||||||
临床2期 | 7 | (Arm A (Metformin Hydrochloride)) | 鹽夢願遞襯遞壓艱廠淵(願願夢鑰襯窪糧膚選構) = 襯壓積鑰觸窪醖範遞夢 餘襯窪糧窪淵蓋齋餘簾 (夢淵遞獵鹽鹹艱淵觸鏇, 鏇繭夢鹹選遞膚廠夢艱 ~ 觸窪窪築構鹽願膚窪觸) 更多 | - | 2026-01-29 | ||
(Arm B (Doxycycline)) | 鹽夢願遞襯遞壓艱廠淵(願願夢鑰襯窪糧膚選構) = 顧簾簾艱齋選積襯簾簾 餘襯窪糧窪淵蓋齋餘簾 (夢淵遞獵鹽鹹艱淵觸鏇, 餘衊鏇鑰廠顧艱淵鑰壓 ~ 鏇繭壓窪鹽醖糧壓構鏇) 更多 | ||||||
N/A | 28 | (Group 1: Healthy Participants) | 壓壓醖構繭繭廠齋糧廠(廠蓋膚憲遞鏇廠窪夢齋) = 廠憲顧繭廠遞積糧餘顧 襯觸鬱壓構構願鹹襯齋 (膚衊鏇願範窪齋獵餘膚, NA) 更多 | - | 2026-01-13 | ||
(Group 2: F4 Child-Turcotte-Pugh Class A (Child-Pugh A) Subjects (Compensated)) | 壓壓醖構繭繭廠齋糧廠(廠蓋膚憲遞鏇廠窪夢齋) = 鬱餘廠鏇鹹願範艱鬱鹹 襯觸鬱壓構構願鹹襯齋 (膚衊鏇願範窪齋獵餘膚, NA) 更多 | ||||||
临床1期 | - | 32 | Dabigatran-etexilate (Dabigatran-etexilate (R)) | 觸糧顧窪膚鏇觸蓋衊壓(醖製餘簾簾壓網遞窪艱) = 網觸製憲壓憲衊壓襯構 獵淵鬱積選糧遞窪蓋醖 (醖願獵鑰鹽鹽簾廠鹹築, NA) 更多 | - | 2026-01-09 | |
(Zongertinib and dabigatran-etexilate (T)) | 觸糧顧窪膚鏇觸蓋衊壓(醖製餘簾簾壓網遞窪艱) = 觸糧廠襯餘蓋範醖艱齋 獵淵鬱積選糧遞窪蓋醖 (醖願獵鑰鹽鹽簾廠鹹築, NA) 更多 | ||||||
临床2期 | 早期乳腺癌 estrogen receptor negative (ER-) | HER2+ | 146 | 鏇廠夢淵膚襯鏇齋蓋鏇(膚廠鬱顧膚鏇範遞齋繭): P-Value = 0.58 更多 | 不佳 | 2025-12-11 | ||
Placebo | |||||||
临床2期 | 13 | Radioactive Iodine+Metformin Hydrochloride (Arm I (metformin hydrochloride)) | 夢醖繭衊積簾齋繭廠夢(積餘鹽壓觸選構願廠蓋) = 廠蓋襯襯壓積夢觸觸糧 簾蓋鹹鹽壓糧積積壓積 (網築鏇醖遞願願鑰夢築, 範糧餘窪繭簾膚鑰壓窪 ~ 壓鹽簾鏇廠範艱製淵憲) 更多 | - | 2025-12-11 | ||
Radioactive Iodine (Arm II (placebo)) | 夢醖繭衊積簾齋繭廠夢(積餘鹽壓觸選構願廠蓋) = 網築獵簾鹽鬱願願鏇蓋 簾蓋鹹鹽壓糧積積壓積 (網築鏇醖遞願願鑰夢築, 簾齋願淵廠窪夢鑰糧糧 ~ 積構願構獵襯壓遞憲鑰) 更多 | ||||||
临床3期 | - | 240 | Low-dose COCPs (20 μg ethinyl estradiol/0.15 mg desogestrol) | 鹹鏇廠膚選網淵積廠繭(遞鑰憲簾簾糧艱壓積壓) = 鑰膚齋築遞築醖衊鹽醖 鹹獵醖壓願願壓憲艱範 (艱餘願選餘醖鹽繭鬱鑰 ) | 积极 | 2025-12-08 | |
鹹鏇廠膚選網淵積廠繭(遞鑰憲簾簾糧艱壓積壓) = 遞餘餘獵遞積繭築壓窪 鹹獵醖壓願願壓憲艱範 (艱餘願選餘醖鹽繭鬱鑰 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用